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CHAPTER I 
 
INTRODUCTION 
 
Background 
 Cancer has afflicted humans for several millennia. The earliest documented case of 
disseminated cancer occurred in a Scythian king on the steppes of southern Siberia 2,700 years 
ago. The oldest written records considered to describe cancer are Egyptian papyri, especially the 
George Ebers and Edwin Smith papyri written 1600-1500 BC, which depict the pharmacological, 
surgical, and magical treatments of the time.
1
 Diagnosis, treatment, and knowledge of cancer 
proceeded slowly through the millennia. In ancient Greece “the father of medicine,” Hippocrates 
(460-360 BC) refers to differences between benign and malignant tumors. However, Gabrielle 
Fallopius (1523-1562) is considered the first to accurately detail the characteristics defining 
benign and malignant characteristics of tumors. In 1740, the first cancer hospital admitted 8 
patients in Reims, France. The citizens’ fear of cancer as a contagious disease compelled the 
hospital to relocate outside the city in 1779. A renowned surgeon, Henri François Le Dran 
(1685-1770), first speculated cancer spread to distal locations through the lymph nodes. In 1829, 
Joseph Recamier coined the term “metastasis” to describe the dissemination of cancer. Armand 
Louis Marie Velpeau (1795-1867) is accredited with postulating the genetic origin of cancer 
through his hypothesis that an intracellular element is responsible for the disease. More than 
eighty years later (1953), Francis Crick and James Watson deciphered the structure of DNA 
(deoxyribonucleic acid) (figure 1-01) and postulated the structure offered a copy mechanism for 
genetic material.
2
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Figure 1-01: The structure of DNA as proposed by James Watson and Francis Crick. Reprinted 
by permission from Macmillan Publishers Ltd: Nature, copyright 1947.
2
 
 
Following the understanding of DNA structure and DNA as genetic material at the 
molecular level, astonishing advancements have been made toward understanding the 
fundamental aspects of cancer at the molecular level.  The new found knowledge led to the war 
against the cancer and to the development of anticancer therapies.  Cancer is a genetic disease 
involving a multistep process directed by the amassing of genetic and epigenetic changes 
culminating in the uncontrolled growth and spread of abnormal cells. A normal healthy body is 
comprised of trillions of cells coexisting in an intricate interdependent environment. Normal 
cells duplicate upon instruction from other cells in their vicinity, collaborating to guarantee each 
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tissue maintains an appropriate size and structure. Cellular collaboration consists in coordinating 
behavior through sending, receiving, and interpreting a complex set of signals that serve to 
control the cells’ social interactions. In healthy cells, the signals regulate the resting, dividing, 
differentiating, and death of the cell as required for the good of the organism. Cancer cells and 
their progeny reproduce in contempt of normal cellular restraints for division forming masses of 
abnormal cells (tumors) that invade nearby tissues and/ or migrate to distant sites forming masses 
of abnormal cells (tumors). As the disease progresses, the cancer cells become more aggressive 
and malignant, eventually disrupting tissues and organs vital to the organism.
3
 
At the molecular level, cancer primarily results from successive mutations that 
collectively alter specific locations in DNA and cause changes in proteins encoded by cancer 
related genes. Mutations observed in cancer cells comprise a diverse range, including point 
mutations, deletions, and insertions involving only a few nucleotides to chromosomal aberration 
encompassing millions of nucleotides. Genes are contained in the DNA molecules of the cell and 
designate a sequence of amino acids required to make a particular protein which will execute the 
function of the gene. Mutations in genes can modify expression, function, and regulation of 
proteins. In cancer related genes, these mutations usually affect the cell’s ability to rest, divide, 
differentiate, or die.  
The gene classes most relevant in cancer are proto-oncogenes, tumor-suppressor genes, 
and other genes that control cell proliferation. Proto-oncogenes promote cellular-growth and 
tumor-suppressor genes inhibit growth. The genes BRAF, c-fos or c-erbb3 are examples of proto-
oncogenes, and RB, p53 and APC are tumor-suppressor genes.
4
 These two gene classes are 
primarily culpable for the unrestrained cellular proliferation in cancer cells. Mutations that 
activate proto-oncogenes functionality generate carcinogenic oncogenes that drive excessive and 
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unconstrained cellular division. Mutations that inactivate tumor suppressor genes contribute to 
cancer through the loss of crucial brakes that prevent uncontrolled growth. Beyond their role in 
cell proliferation, oncogenes and tumor suppressor genes determine cell fate through 
differentiation, senescence, and apoptosis.
3
 These genes have an essential and irreplaceable role 
through their regulation in the natural life of cells. The transition of normal cells toward cancer 
usually involves both mutations activating proto-oncogenes and deactivating tumor suppressor 
genes. Ultimately it is cooperating genetic defects that result in dysregulation of proliferation, 
differentiation, and apoptosis that initiate tumorigenesis.
5, 6
  
 
Chemical and Environmental Carcinogenesis 
The incidence of cancer has noticeably increased in recent decades in concurrence with 
increases in unhealthy behavior in the general population, life expectancy, and the presence of 
carcinogens in consumer products and the environment.
7
 Humans are perpetually exposed to 
exogenous and endogenous chemicals known to induce DNA mutations and cancer. These 
chemicals are widely referred to as carcinogens. An individual’s personal and cultural habits are 
often the prevailing cause of human cancer. Exposure to carcinogens occurs due to the chemicals 
presence in food, air, consumer products, or water or the chemical products of cell metabolism. 
Examples of environmental carcinogens include tobacco smoke, diesel exhaust, asbestos, 
radiation, and some viruses.
8
  
The first evidence of the carcinogenic effects of exogenous chemicals was found in the 
18
th
 century. In 1761, Dr. John Hill linked the development of nasal cancer to the excessive use 
of tobacco snuff.
9
 One of the first occupationally related cancers was identified 14 years later by 
Sir Percival Pott. Sir Percival Pott related increased incidence of scrotal cancer in chimney 
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sweeps to a continuous exposure to soot.
10
 In 1915, Yamagiwa and Ichikawa were the first to 
experimentally provoke carcinogenesis through repeatedly painting coal tar on the ears of 
rabbits. The coal tar induced multiple squamous cell carcinomas in the painted areas.
11, 12
 The 
experiments led to identification of a pure carcinogenic chemical, 1,2,5,6-dibenzanthracene a 
polycyclic aromatic hydrocarbon (PAH) by Ernest Kenneway and his coworkers.
13
 Another 
PAH, pentacyclic benzo[a]pyrene was later identified as a tumorigenic component of coal tar. In 
an analogous study, 2-naphthylamine (2-NAPH, 1.01) was shown to induce bladder tumors in 
canines. Other sources evidenced several simple aromatic amines (SAA) in addition to 2-NAPH 
were potent carcinogens in animal studies, including 4-aminobiphenyl (4-ABP, 1.02), o-toluidine 
(o-tol, 1.03), and 2-aminofluorene (2-AF, 1.04) (figure 1-02). Aromatic amines are rather widely 
used in the aniline dye industry, as antioxidants in the production of rubber and cutting oils, as 
pesticides and in pharmaceutical chemistry as the initial or intermediate products.
14,
 
15  
Figure 1-02: Structures of simple aromatic amines. 
By the 1940s it had been found that aromatic amines, PAH’s and other environmental 
media were factors in inciting lung, bladder, liver and possibly breast cancer. The results were 
the first evidence that structurally defined compounds that existed in industry were related to 
carcinogenesis in humans. At present, a great variety of compounds have been identified as 
carcinogenic to humans. By the end of 1970’s researchers were questioning what the mechanism 
of action of these carcinogens in genotoxicity. Of particular importance, the work of the Millers 
and others showed that most carcinogens were metabolized or bio-activated to more chemically 
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reactive species (metabolite).
16, 17
 These species were labeled the “ultimate carcinogens”. The 
“ultimate carcinogen” was initially considered to be an electrophile formed in vivo with a finite 
stability that could diffuse limited distances to covalently modify DNA. The belief the species 
would diffuse limited distances led to the idea that carcinogens would be activated in vivo by 
nuclear enzymes.
18, 19
 Years later, it was demonstrated that a carcinogen could be activated to a 
form capable of covalently modifying DNA with in hepatocytes, and the reactive form could be 
trapped outside of the cell.
20
 In addition, enzymes that are involved in the detoxification of cells 
were able to activate chemical carcinogens. For example, cytochrome P4501A2 initially 
activates 4-ABP through N-oxidation generating a reactive species that can covalently modify 
DNA.
21, 22
  
 
The Role of DNA adducts in Carcinogenesis 
As mentioned previously Watson and Crick determined the structure of DNA through X-
ray diffraction images. They reported “the novel feature of the structure is the manner in which 
the two chains are held together by the purine and pyrimidine bases… the (bases) are joined 
together in pairs, a single base from one chain being hydrogen-bonded to a single base form the 
other pyrimidine for bonding to occur…Only specific pairs of bases can bond together. These 
pairs are: adenine (purine) with thymine (pyrimidine), and guanine (purine) with cytosine 
(pyrimidine).” 
As stated in Watson and Crick’s report, the outer portion of the DNA double helix is 
alternating ribose sugar molecules that are linked by phosphate groups. The two strands extend 
in opposite directions with the nitrogenous bases “inside” the two strands like rungs on a ladder. 
Each complete “rung in the ladder” consists of a phosphate group, ribose group, and the 
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nitrogenous base that spans space between the strands, which grouped together are called a 
nucleotide. Within the DNA double helix structure, each nucleotide of one strand is tightly base-
paired with its complementary nucleotide on the opposite strand.
2
 The right-handed helix 
discovered by Watson and Crick is known as B DNA. This is the most common form of DNA 
found in organisms at neutral pH and physiological salt concentrations. Other forms of DNA 
reported in organisms are A and Z DNA.
23,24
 
As mentioned, DNA holds the genetic information of the organism. The order of the 
bases in the DNA sequence is the genetic code, where an open reading frame can be transcribed 
into mRNA and later translated into proteins, required for functioning of living organisms. Each 
amino acid of a protein is coded buy three bases of a DNA sequence. Cellular division requires 
proper replication of the genetic code for biological functions to be conserved. Normal 
replication involves high fidelity polymerases (pol) that strongly favor insertion of correct 
nucleotide. These are members of the B-family of DNA polymerases, and they include δ, ε, and 
α. These polymerases misinsert one base for every one million bases that are copied25. Several 
replicative polymerases contain a 3’5’ exonuclease activity, which processes the removal of 
incorrect nucleotides in the event of misincorporation. However, damaged or modified DNA 
can halt replication if not repaired. Without repair, accumulated DNA damage leads to 
mutations. Intricate DNA repair systems maintain genome integrity, in the event that replication 
errors, environmental insults, and the cumulative effects of age damage the DNA. These repair 
systems include nucleotide excision repair (NER), base excision repair (BER), and mismatch 
repair (MMR). Failure of these repair system results in the accumulation of damage.
26
 The 
reaction of carcinogens with DNA is considered one of the earliest events in the initiation of 
cancer. Many carcinogens react with DNA to form covalent complexes modifying a base in the 
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sequence. The modified base is referred to as DNA adduct. DNA adducts not repaired prior to 
replication can cause mutations in the genes involved in important cellular functions as was 
discussed earlier.   
Carcinogens often induce a complex set of mutations thought to be initiated when a DNA 
polymerase encounters a mutagenic DNA adduct during replication. Adducted DNA may cause 
mutations through misincorporation or slippage by a DNA polymerase during replicative 
bypass.
27
 Endogenous DNA damage results through insults to DNA by reactive oxygen species 
(ROS) such as hydroxyl radicals, spontaneous depurinations or depyrimidination, and 
deamination of the bases adenine, cytosine or guanine. This endogenous damage also contributes 
to mutagenesis.
28
 As discussed earlier, carcinogens are often metabolized to more reactive 
species that can covalently modify DNA. Carcinogens requiring metabolic activation include 
polycyclic aromatic hydrocarbons, aromatic amines, nitrosamines, aflatoxins, other mycotoxins, 
some alkylating agents and estrogens.
29
 DNA adduct formation is now an expected attribute of 
the most potent carcinogens. Therefore, formation of such adducts is the basis for most strategies 
in molecular epidemiology.
30,31
 
Metabolic activation of carcinogens typically results in a transitory electrophilic 
compound capable of reacting at nucleophilic sites of cellular molecules, more notably DNA.  A 
variety of enzymes are involved in xenobiotic metabolism such that both oxidizing and 
conjugating enzymes activate carcinogens toward DNA-binding. The list of enzymes include 
cytochrome P450s, glutathione-S-transferases, sulfonyltransferases, and N-acetyl-transferases
32
. 
Once the carcinogen has been activated, the level of adduction to DNA is directly related to 
carcinogenic potency.
33,34
 In addition, the stability of the DNA adducts is affiliated with the 
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probability of tumorigenesis.
35
 However, there is yet no simple answer for the relevance of DNA 
adduct formation to assessing cancer risk. 
Once DNA adducts form, a complex series of events that leads to cancer. DNA adducts 
that evade the cellular repair mechanisms may lead to permanent mutations.
36
 Failure of a repair 
pathway to recognize DNA damage will generally result in the stalling of normal genome 
replicative polymerases, and without an alternative system to process the replication bypass of 
the damaged adduct apoptosis can occur. The enzymes of this alternative system are translesion 
synthesis (TLS) polymerases. Translesion synthesis polymerases are responsible for bypass of 
DNA adducts or lesions that block replication by the general genome replicative 
polymerases.
37,38
 These TLS polymerases are in the Y-family and B-family of polymerases. The 
human TLS polymerases are pol η, κ, ι, and Rev1 from the Y-family and pol ζ from the B-
family. Several other bypass polymerases have been discovered, but their role in TLS is not well 
defined. The TLS polymerases are notorious for their low fidelity resulting in frequent 
misincorporation of nucleotides. The low fidelity is usually attributed to the TLS polymerases 
larger active site compared to replicative polymerases. For example, the Y-family polymerase 
DPO4 from archaeal bacteria Sulfolobus solataricus can accommodate two nucleotides within 
the active site. In addition, Y-family polymerases also lack the 3’5’ exonuclease activity of 
replicative polymerases, and the TLS polymerase disassociate after the insertion of only a few 
nucleotides. While TLS polymerases allow the bypass of DNA lesions that halt replication, the 
low fidelity of these polymerases results in the misincorporations and other mutagenic events.   
Events leading to cancer include spontaneous mutations such as base substitutions and 
frameshift mutations that accumulate throughout the genome in the absence of repair. The 
complexity of DNA-adduct derived mutagenesis is related to structural and biological factors. 
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Structural factors include DNA sequence hotspots such as the NarI sequence, which is a hotspot 
for frameshift mutations. When a mutation occurs in a critical gene and the genes function is 
affected, carcinogenesis may result. Proto-oncogenes and tumor suppressor genes which regulate 
cell proliferation are examples of critical genes.
39
 
 
Heterocyclic Amines 
The development of human cancer is strongly associated with exposure to environmental 
carcinogens. As mentioned earlier, food or diet is a common route of exposure. One class of 
compounds with the most common route of exposure through diet is heterocyclic aromatic 
amines (HAA). This class of compounds forms in high temperatures when cooking meat through 
the Maillard reaction.
40,41
 The term “Maillard” reaction describes the reaction between amines 
and carbonyl compounds, especially reducing sugars, during cooking. The reaction is induced at 
temperatures above 300 °C. Formation at lower temperatures only occurs in the cooking of meats 
with higher concentrations of amino acids and sugars. Incidentally, the Maillard reaction is of 
major significance for the development of flavors, texture and brown pigments generated when 
heating certain foods, and also contributes to the palatability of that food.
41
  
 
Mutagenicity of Heterocyclic Aromatic Amines 
The relevance of HAAs was revealed in the early 1970s.  Inspired by a study showing mutagens 
in cigarette smoke, Takashi Sugimura found that particles of smoke, produced by cooking 
proteinaceous food contained significant quantities of mutagens.
42,43
 The mutagens in fumes of 
frying meat or fish was shown using the Ames Salmonella typhimurium test. The Ames test is an 
easy and sensitive assay to detect potentially genotoxic carcinogens by ascertaining their  
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Figure 1-03: Mutagenicity of several HAAs in the Ames TA98 assay 
mutagenicity in a bacterial system.
44
 The discovery of HAAs had considerable importance in the 
scientific community. These compounds are isolated from food prepared under normal cooking 
conditions, and therefore humans are continually exposed. The HAAs are highly mutagenic in 
the Ames test (Figure 1-03). More than twenty HAAs have been identified to date (Figure 1-
04).
43
 As a class of compounds, HAAs have also proven mutagenic in mammalian studies in 
vitro and in vivo. Inflammation, smoking, and diet are responsible for 25-30% of cancers.
45,46
 
Human exposure to HAAs is modest, one study estimates exposure at ∼60 ng/day.47 Though the 
levels of exposure are low, HAAs are still thought to contribute to the etiology of human 
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cancer.
48
 They are believed to associated with pancreatic, colon, breast and prostate 
cancers.
49,50,51,52
 The International Agency for Research on Cancer (IARC) have classified many 
HAAs as either 2A (probable human carcinogens) or 2B (possible human carcinogens) agents.  
More than Twenty years of studies evaluating HAA formation in meats have resulted in 
several methods to reduce HAA intake. Suggested methods to reduce HAA intake include 
cooking with marinades rich in polyphenols
51,53,54
 and not cooking meat over an open flame,
55
 
flipping meat often
56
 or microwaving
57
 have all been shown to reduce the formation of HAAs. 
 
2-Amino‐3-methylimidazo‐[4,5-f]quinoline (IQ) 
Of the characterized HAAs, 2-amino‐3-methylimidazo‐[4,5-f]quinoline (IQ) (1.06) is one 
of the most mutagenic compounds. The International Agency for Research on Cancer (IARC) 
classified IQ (1.06) as a “class 2A” toxin, meaning that IQ is probably carcinogenic to humans. 
Class 2A is the highest classification of any HAA.
58
 IQ (1.06) is found in cooked meats at parts 
per billion (ppb) levels.
59,60
 IQ (1.06) is also present in tobacco smoke.
61
 In Ames’ Salmonella 
typhimurium assay, IQ (1.06) is a potent inducer of two-base deletions in the CpG dinucleotide 
repeat sequences of the HisD3052 target sequence (5ʹ -CGCGCGCG-3ʹ ), as are many other 
aromatic amines and nitrosoaromatic compounds.
44
 Studies in which laboratory animal were 
exposure to IQ (1.06) have indicated that IQ is an animal carcinogen. For instance, rats exposed 
to IQ (1.06) through intragastric intubation were found to form tumors in mammary glands, liver 
and ear ducts.
62
 Cynomolgus monkeys also exhibited high levels of hepatocellular carcinomas 
when IQ (1.06) was administered by gavage directly into the stomach.
63
 IQ (1.06) is primarily 
metabolized by cytochrome P450 1A2, with cytochromes P450 1A1, 1B1, and 3A4 playing a 
minor role in the metabolism.
64
 Cytochrome P450 1A2 oxidizes IQ (1.06) to the N-  
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Figure 1-04: 19 HAAs Characterized to Date 
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hydroxylamine (Scheme 1-01). The N-hydroxylamine is then acetylated by N-acetyltransferase 
(NAT1 and NAT2), particularly NAT2, generating N-acetoxy-IQ. Solvolysis may follow 
acetylation yielding an aryl nitrenium ion. Either N-acetoxy-IQ or the aryl nitrenium ion act as 
the “ultimate carcinogen” that covalently modifies DNA.64 At the N-hydroxylamine stage,the 
reaction can continue in the absence of transferase enzymes under acidic conditions.
65
 The 
hydroxylamine may become protonated, and the loss of water through solvolysis will result in 
the reactive aryl nitrenium ion. However, the metabolism is much more efficient when catalyzed 
by NAT enzyme. Therefore, tissues with NAT2 activity are more susceptible to formation of IQ 
(1.06) adducts. The major DNA adducts formed from most aryl nitrenium ions occur at the C8 
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atom of 2ʹ-deoxyguanosine (dG), and a minor product forms at the N2-posistion of dG. The dG-
N
2
-IQ (1.27) adduct was shown to be more persistent in rodents due to slower repair.
66
 The 
formation of these adducts may cause coding errors at the time of replication. As mentioned 
earlier, there are repair mechanisms (BER, NER, and MMR) that may repair the damage of dG-
IQ adducts. In the absence of repair, the dG-IQ adduct could lead to point mutations, deletions, 
insertions, or gross chromosomal aberrations.
67
 
 
NarI Recognition Sequence 
The NarI recognition sequence is a DNA sequence frequently used to understand the 
mutagenicity of aromatic amines.
68, 69, 70
 The NarI sequence, 5ʹ-G1G2CG3CC-3ʹ, contains a GpC 
dinucleotide repeat. This sequence has exhibited sequence dependent mutagenic properties in 
Eschericia coli (E. coli).
71
 Repeat sequences are known to produce frameshift mutations in much 
higher frequencies than non-repeat sequences.
72, 73, 74
 The NarI gene codes for the cytochrome b 
(γ subunit) of a nitrate reductase enzyme that allows the E. coli to use nitrate as an electron 
acceptor during anaerobic respiration.
75
 The NarI recognition sequence is a hotspot for 
frameshift mutations. This site has displayed a mutagenic frequency of 10
7
 in E. coli over 
background mutagenicity when G3 is modified by the aryl amine N‐acetyl‐2-aminofluorene 
(AAF) (1.28) of dG.
76
 When the frameshift mutation occurs in E. coli, binding of the NarI 
enzyme to the membrane may be reduced. The binding of the heme may also be reduced, since 
heme binding is associated with the γ subunit.77 Streisinger predicted that repeat sequences 
would be hotspots for mutations.
78, 79, 80
 The hypothesis was that either the template or the 
daughter strand would be able to slip, producing a misalignment of the duplex with bases pushed 
out of pairing. This would ultimately yield a frameshift mutation.
78
 The Ames tester strain TA98 
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contains an island of (CpG)4 in the HisD3052 target sequence (5ʹ-CGCGCGCG-3ʹ).
44
 This is one 
example of the sequence dependence of the DNA adduct mutagenicity. As mentioned, the NarI 
restriction sequence 5ʹ-CG1G2CG3CC-3ʹ is a notable mutational hot spot for frameshift mutations 
for the C8-dG adduct of N-acetyl-2-aminofluorene in E. coli, especially when the adduct is 
located at G3. However, the N-acetyl-2-aminofluorene adduct in the NarI sequence induces only 
base substitutions in simian kidney cells.
81,82,83
 
 
TLS Polymerases η, ι, Rev1, κ, and ζ 
Bulky DNA adducts such as dG-C8-IQ (1.26) and dG-N
2
-IQ (1.27) block the genome 
replicative DNA pols. In this case, replication of the genome can be rescued by the specialized 
TLS DNA pols than can bypass bulky lesions.
84,85,86,87
 These TLS pols are actually more error-
prone even with undamaged templates. However, some TLS polymerases can bypass specific 
DNA damages efficiently and with high fidelity.
88, 89
 In eukaryotic cells, efficient TLS is carried 
out conjointly by two sequential steps.
90, 91
 First, a TLS pol replaces the stalled replicative pol 
and inserts a nucleotide opposite the DNA lesion. Subsequently, the same TLS pol may either 
extend the primer a few nucleotides beyond the lesion, or it may be replaced by another TLS pol. 
In either case, the primer is extended a few nucleotides beyond the lesion site before the pol is 
replaced by the replicative pol to continue DNA synthesis. Studies have found a requirement of 
accessory proteins for efficient TLS.
92,93
 In eukaryotic cells, TLS is carried out by pol η, pol ι, 
pol κ and Rev1 of the Y-family pols and pol ζ of the B-family enzymes.87, 94 
 Pol η and other Y-family polymerases are less inhibited by the geometric distortions 
imposed by the presence of lesions in DNA. This allows pol η to replicate through DNA lesions, 
which typically stall the polymerases typically responsible for duplicating the genome. The 
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ability of TLS polymerases to better tolerate the geometric distortion of a damaged base and/or a 
mismatched base pair in their active sites has been substantiated from steady-state kinetic 
analyses with yeast and human Pol η, which shows the misincorporation of nucleotides with a 
frequency of ∼10−2 to 10−3.37, 95, 96 Human pol η stands apart from other TLS polymerase through 
the ability to replicate past cis-syn deoxythymidine-deoxythymidine (dTyd-dTyd) dimer by 
inserting two dATP’s opposite the dimer with similar efficiency and fidelity as opposite two 
undamaged dTyd’s.95 Defects in the gene coding of the human pol η cause the cancer 
predisposition disorder, xeroderma pigmentosum variant (XPV).
97,98
 Human pol η also plays an 
important role in the efficient and accurate replication through the 8-oxoguanine (8-oxo-dG) 
lesion, where other TLS polymerase favor misinsertion of dA opposite 8-oxo-dG.
99,100
 However, 
a low but significant level of dATP is also inserted by pol η. In addition, abasic sites are strong 
blocks to replication by pol η.101 It is noteworthy that pol η is inhibited by numerous lesions 
which severely impinge on the minor groove and/or disrupt Watson-Crick hydrogen bonding of 
base pairs. Examples of these adducts include N
2
-dG adducts of benzo[a]pyrene (1.05), 7,8-diol 
9,10-epoxide (BPDE)
102
 and butadiene epoxide;
103
 also, the acrolein-derived adduct γ -hydroxy-
1,N
2
-propano-deoxyguanosine (γ-HOPdG)104 and 1,N6-etheno-deoxyadenosine.105 
 Replicative pols as well as TLS pol η and κ form the four possible correct base pairs with 
nearly equivalent catalytic efficiencies, meaning that dCTP is inserted to form GC base pair as 
efficiently as dTTP is inserted to form AT base pair. Pol ι is a notable exceptions to this rule.37 
Pol ι incorporates nucleotides opposite the four template bases with very different efficiencies 
and fidelities. Specifically, pol ι incorporates nucleotides opposite template purines with a much 
higher efficiency and fidelity than opposite template pyrimidines.
106, 107, 108, 109, 110
 Pol ι exhibits 
the highest efficiency and fidelity opposite template dA. The misincorporation frequencies for 
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each of the template bases are as follows: opposite A ∼10−3 to 10−5, opposite dG ~10
-1
, opposite 
dC ∼10−1 to 10−2, and opposite dT misincorporation of dG is 10 fold greater than dA, and dT is 
inserted as efficiently as dA.
106, 109, 110
 For most mispairs, pol ι extends from the mispaired primer 
terminus with efficiency similar to formation of the mispair. However, it extends the primer-
template G:T and T:G mispairs as efficiently as extension from the correct A:T and C:G pairs.
111
 
Unlike pol η, pol ι is able to incorporate nucleotides opposite an abasic site106. A more specific 
role of pol ι in lesion bypass has emerged from evidence of its proficient ability to incorporate 
nucleotides opposite of an N
2
-adducted guanine.
110
 The N
2
 group of guanine can conjugate with a 
variety of endogenously formed adducts. In contrast to replicative/TLS polymerases, pol ι 
synthesizes DNA using Hoogsteen base pairing, where the primer terminus base is in the syn 
conformation.
112
 
 The TLS polymerase Rev1 is more accurately referred to as a deoxycytidyl transferase 
due to preferential insertion of dCTP.
37,
 
113
 Rev1 typically functions in conjunction with B-
family TLS Pol ζ , which is comprised of the Rev3 and Rev7 proteins. For example mutagenesis 
induced by UV lesions 
114, 115, 116, 117
 or from abasic sites,
118
 requires all three proteins. Rev1 
misincorporates nucleotides opposite the template with a frequency of ∼10−3 to 10−4, and also 
misinserts a dCTP opposite templates T, A, and C with frequencies of ∼10−2 to 10−3.119 Rev1 is 
necessary for most base substitution mutations induced by UV light,
114
 and is indispensable for 
mutagenesis resulting from TLS through abasic sites.
120
 However, the role of Rev1 with these 
lesions is not C incorporation.
120,
 
121, 122
 In addition, AAF bound to the C8 of a dG presents a 
strong block to nucleotide incorporation by Rev1. However, studies have implicated a 
requirement for the Rev1 protein to replicate through the AAF adduct located in a double-
stranded plasmid without use of Rev1 of dCTP transferase activity.
123
 The implication of these 
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studies is that Rev1 has a role as an accessory subunit in the TLS of several lesions. Studies 
indicate the role of Rev1 as an accessory subunit is typically closely associated with assembly of 
pol ζ.123, 124 Biochemical studies indicate Rev1 proficiently inserts dCTP opposite γ-HOPdG.125 
Rev1 can proficiently incorporate a dC opposite the various N
2
-adducted dG adducts.
125, 126, 127, 
128
 Structural studies elucidating Rev1 mechanism of action suggest Rev1 dCTP transferase 
activity will show specificity toward insertion opposite of N
2
-adducted dG adducts.
129
 Rev1 acts 
by swinging the template adducted G out of duplex at ~90
0
 and forming 2 H bonds on Hoogsteen 
edge between N
7
 and O
6ˆ and Met685 and Gly686.129 The exclusion the template G from the DNA 
places the N
2
 of G in a large (solvent-filled) void between PAD and fingers domain, where an 
adduct such as γ-HOPdG would be sterically unhindered.129 In addition to the suggested role of 
Rev1 in the assembly of pol ζ, more recent studies implicate mouse and human Rev1 in the 
assembly of pol η, pol ι, and pol κ.119, 130, 131, 132, 133  
 Pol κ belongs to the DinB subfamily of Y-family DNA polymerases including E. coli 
DinB (Pol IV), archaeal Dbh, and Dpo4 proteins.
37, 130
 Pol κ is distinct among Y-family 
polymerases for its nucleotide incorporation specificity and mismatch extension ability. Pol κ is 
considered the most faithful of all Y-family DNA polymerases with a misincorporation 
frequency of ∼10−3 to 10−4 opposite all four template bases.37, 134 In contradiction to its fidelity, 
Pol κ is a proficient extender of mispaired primer termini. Pol κ extension frequency from a 
mispaired termini is 10
−1
 to 10
−2
.
37, 135
 Several studies support that pol κ is specialized in 
performing error-free bypass of bulky minor groove N2-deoxyguanine adducts among 
other lesions.136 Investigations also support that pol κ may have a critical role in limiting 
mutagenesis from specific bulky lesions such as benzo[a]pyrene (1.05) adducts. 135, 136, 137, 
138, 139, 140, 141, 142, 143, 144  
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 DNA polymerase ζ is a TLS DNA pol sharing sequence similarities within the catalytic 
domain of its fellow the B family of DNA pols pol δ, pol ɛ and pol α.136, 145, 146, 147, 148, 149 Pol ζ 
consists of both Rev7 and Rev3 proteins.
136, 150
 Pol ζ possesses a lower processivity and is devoid 
of the 3′ → 5′ proofreading exonuclease activity present in most B-family DNA pols. Rev3 alone 
is capable of polymerization; however, association of Rev3 with Rev7 forms a more stable 
complex and significantly enhances the polymerase activity of Rev3 by 20–30 fold. This 
suggests that Rev7 functions as a processivity factor for pol ζ. Recently, the two accessory 
subunits (pol 31 and pol 32), which are known to associate with the catalytic subunit (pol 3) of 
yeast pol δ, were also identified in a complex with pol ζ. Furthermore, the presence of pol 31 and 
pol 32 with pol ζ enhances the efficiency of TLS in yeast.136, 151, 152 Human analogs of pol 31 and 
pol 32 identified as pol D2 and pol D3 have been isolated in complex with human pol ζ, and the 
full complex exhibited polymerase activity in vitro.
136, 153
 Thus, pol ζ is now considered to be a 
four subunit polymerase.
136
 Compared to the other Y-family pols, pol ζ is a high-fidelity enzyme, 
since it misincorporates nucleotides opposite all four template bases with the same frequency as 
pol α, ∼10−4.37, 106, 120, 154 Pol ζ differs significantly from other DNA pols in its very proficient 
ability to extend from mispaired primer termini, which occurs with a frequency of ∼10−1 to 10−2. 
Pol ζ is very inefficient in replicating through most DNA lesions, which results from its inability 
to incorporate nucleotides opposite them.
37, 136
 Pol ζ is particularly specialized to extend distorted 
base pairs, such as mismatches that may result from inaccurate base insertion or a base pair 
involving a bulky DNA lesion.
155,
 
156
 Thus, the primary role of pol ζ in TLS is performing 
extension following insertion opposite of the lesion by another TLS pol.
157
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Dissertation Aims 
As previously discussed, carcinogens can induce mutations. These mutations are thought 
to be initiated at the time of replication when a DNA polymerase encounters a carcinogen-
modified nucleobase. Misincorporation of the wrong base by a DNA polymerase results in a 
mutation in the sequence, and an accumulation of persistent mutations and other DNA damage 
will ultimately lead to cancer.  
The aim of this dissertation is to examine the in vitro replication of the dG-C8-IQ (1.26) 
and dG-N
2
-IQ (1.27) adducts by translesion DNA polymerases to determine their contributions 
to the observed mutagenic spectra. In this case, IQ adducts are known to induce GA transitions 
and GT transversions in eukaryotic cells.  
Chapter II 
In Chapter II, the in vitro replication of the dG-C8-IQ (1.26) adduct is examined by TLS 
polymerases in relation to the mutagenic profile observed through small interfering ribonucleic 
acid (siRNA) knockdowns of TLS polymerases in eukaryotic cells. This allowed elucidation of 
the polymerases involved in the mutations initiated by translesion bypass of the dG-C8-IQ (1.26) 
adduct. The aims of Chapter II are: 
1. Discussion of the mutagenic profile observed for dG-C8-IQ (1.26) through siRNA 
knockdowns of TLS polymerases in HEK293T (human embryonic) kidney cells. 
2. Examination of the previously unreported translesion bypass of dG-C8-IQ (1.26) by 
yeast DNA polymerase ζ and the deoxycytidine triphosphate (dCTP) transferase 
human Rev1. 
3. Examination of the extension from a mismatched primer termini, dG-C8-IQ:N where 
N is A or T by TLS polymerases ζ, κ, ι, and η. 
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Chapter III 
In Chapter III, similar to Chapter II, the in vitro replication of the dG-N
2
-IQ (1.27) adduct 
is examined by TLS polymerases. The in vitro replication results are related to the mutagenic 
profile observed through siRNA knockdowns of TLS polymerases in HEK293T kidney cells. 
This allowed elucidation of the TLS polymerases involved in the mutations initiated by 
translesion bypass of the dG-N
2
-IQ (1.27) adduct. The aims of Chapter III are: 
1. Discussion of the mutagenic profile observed for dG-N2-IQ (1.27) through siRNA 
knockdowns of TLS polymerases in HEK293T kidney cells. 
2. Examination of the previously unreported translesion bypass of dG-N2-IQ (1.27) by 
yeast DNA polymerase ζ and the dCTP transferase human Rev1. 
3. Examination of the extension from a mismatched primer termini, dG-N2-IQ:N where 
N is A or T by TLS polymerases ζ, κ, ι, and η. 
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CHAPTER II 
 
REPLICATION OF THE C8-DEOXYGUANOSINE IQ ADDUCT 
 
Introduction 
TLS: Incorporation of Nucleotides Opposite of dG-C8-IQ 
dG-C8-IQ (1.26) is the major adduct formed with dG in DNA and the bio-activated form 
of the probable carcinogen IQ.
1, 2, 3 
Previously the in vitro replication of the dG-IQ adducts has 
been investigated. The IQ lesions were site specifically incorporated into 27mer templates at the 
G1 and G3 positions of the NarI recognition site.
4
 As discussed in Chapter 1, sequences with GC 
dinucleotide repeats are susceptible to frameshift mutations. As a result, these sequences are of 
interest to determine if a particular DNA adducts is capable of inducing frameshift mutations. 
For example, the replication of the dG-AAF adduct especially when located at the iterated G3 
positon (5ʹ-G1G2CG3CC-3ʹ) is susceptible to frameshift mutations in E. coli.
5, 6, 7
 However, dG-
AAF induces only base substitutions in simian kidney cells.
5, 6, 7
 The previous studies revealed 
the ability of TLS pols η, κ, ι and the B-family replicative pol δ to incorporate nucleotides 
opposite of and past both the dG-C8-IQ (1.26) and dG-N
2
-IQ (1.27) lesions. Replication by pol δ 
is completely blocked by the IQ adducts. When present in the NarI restriction site, human pol η 
extended primers beyond dG-C8-IQ (1.26) more efficiently than pol κ and much better than pol 
ι.4 TLS by pol η was determined to be largely error-free for the dG-C8-IQ (1.26) lesion. Pol η 
inserted dCTP and dATP opposite of the dG-C8-IQ (1.26) lesion, and the misinsertion frequency 
of dATP by pol η was .0097 at G1 and 0.43 at G3. However, no extension was observed when pol 
η inserted dATP opposite of the lesion.4 Human pol κ was capable of inserting dCTP and dGTP 
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opposite of the dG-C8-IQ (1.26) adduct, and then further extension was blocked.
4
 The 
misinsertion frequency of dGTP by pol κ was .047 at G1 and .069 at G3. The same study 
revealed human pol ι would insert dCTP or dTTP opposite of dG-C8-IQ (1.26) lesion.4 Pol ι 
was incapable of further extension following insertion, and the reported misinsertion 
frequency of dTTP was 2.0 at G1 and 5.8 at G3.4  The misincorporation results of this in vitro 
study suggested that TLS replication of dG-C8-IQ (1.26) could result in GCAT transitions, or 
the transversions GCTA, GCCG.4 Further studies in HEK93T cells would reveal that the 
observed mutations resulting from replication of dG-C8-IQ (1.26) were the point mutations, 
GA and GT.8 Thus, the in vitro insertion of dGTP by pol κ was irrelevant to the mutagenesis 
induced by the lesion. 
 
Induced Mutagenesis siRNA knockdown of TLS Polymerases 
The mutagenesis of the dG-C8-IQ (1.26) adduct in HEK293T (human embryonic) kidney 
cells has been investigated utilizing siRNA knockdown of the TLS pols.
8
 This study specifically 
investigated the role of various TLS pols in bypassing dG-C8-IQ (1.26) located at the three 
guanine positions of the NarI restriction site in human cells.
8
 The complete inability to express 
genes for TLS polymerases in humans could result in cell death.
9, 10
 siRNA knockdown  involves 
partial silencing of a target gene.
11
 siRNA knockdown is utilized in the case that the target 
protein is critical to cell viability. The result of the technique is that the amount of protein is 
reduced to the point that loss of function yields critical data regarding the role of the protein.
11
 In 
this particular investigation, the siRNA knockdown of the targeted TLS pol(s) resulted in at least 
70% silencing. The lesion containing or unmodified (for control) oligonucleotide was ligated in 
to a plasmid vector. Then, following siRNA knockdown of the target TLS pol (s), the plasmid 
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was replicated in HEK293T cells. Ultimately, the replication products were recovered. Products 
not hybridizing to the complementary wild-type 14mer sequence were considered mutants and 
were subjected to sequence analysis. The negative control, where TLS was not reduced, revealed 
that dG-C8-IQ (1.26) is bypassed more efficiently at G3 > G2 > G1 (81% TLS at G3 vs 58% TLS 
at G1) (Figure 2-01).  The TLS pols η, κ, ι, ζ and Rev1 were evaluated for bypass of dG-C8-IQ 
(1.26). Each of the TLS pols evaluated were involved in replication of dG-C8-IQ (1.26) adduct 
to some extent as indicated by the reduction in the % TLS relative to wild-type (WT) for each 
knockdown performed (Figure 2-01). The simultaneous knockdown of pol η/pol ζ showed the 
most pronounced effect on TLS with up to a 70% reduction in viability of the dG-C8-IQ pol ζ 
play critical roles in TLS of dG-C8-IQ (1.26), although pol κ also is important. The DNA  
 
 
Figure 2-01. The effect of the siRNA knockdowns of TLS polymerases on the percentage of replicative bypass of 
the dG-C8-IQ. The method by which the percentage of TLS in observed for the depicted knockdowns is described in 
the corresponding publication.
8
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sequencing analysis revealed that GT transversions were the main mutations observed, 
however, some GA transitions were also seen. Significantly, no frameshift mutations were 
observed. The analysis also showed that dG-C8-IQ (1.26) is mutagenic in HEK293T cells in all 
three sites (figure 2-02). The order of mutational frequency (MF) for each adducted G was G3 > 
G2 > G1 with fifty percent MF at G3. Knockdown of pol η resulted in an increase in MF, which 
was most pronounced at G3 (26% increase in MF in the progeny from G3) (Figure 2-02). 
Therefore, pol η is essential to error free bypass of the dG-C8-IQ (1.26) lesion as there are fewer 
mutations during TLS by active pol η. In contrast, MF at each site was decreased when pol κ, ι, ζ 
or Rev1 was knocked down (Figure 2-02). Thus, these polymerases are collectively responsible 
for the error-prone TLS of dG-C8-IQ (1.26). The most pronounced decrease in MF at each site 
was in pol κ-knockdown cells. MF of the progeny derived from the G1, G2 and G3 constructs, 
respectively, were reduced by 47%, 67% and 38% upon knockdown of pol κ. In addition, the 
simultaneous knockdown of two pols showed that the lack of each two-pol combination resulted 
in further decrease in MF indicating a more error prone processivity. For example, a decrease in 
MF was observed when pols η and κ were simultaneously knocked down (Figures 2-02), where 
the individual polymerases exhibited opposite effects. In addition, the simultaneous knockdown 
of pol ζ and Rev1 together, and that of pol κ, ζ, and Rev1 together, decreased MF at each 
adducted guanine in the sequence much more than anyone pol individually (Figures 2-02). 
Simultaneous knockdown of pols κ and ζ exhibited a remarkable synergy on the reduction of MF 
(Figure 2-02). Triple-pol knockdown of pol κ, pol ζ and Rev1 further reduced the MF of the 
progeny from each dG-C8-IQ (1.26) construct. Based on this result, the study concluded that the 
most critical role in the error-prone TLS of the dG-C8-IQ (1.26) adduct is played by pols κ and ζ, 
whereas pol ι likely has a relatively minor role. The study also concluded that pol η plays a  
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Figure 2-02. The depicted results represent the mutational frequency resulting from TLS of dG-C8-IQ at G1, G2 and 
G3 of the oligonucleotide constructs in HEK293T cells where the cells were transfected with NC siRNA (WT) or 
siRNA for single, double or triple pol(s) knockdowns (according to each bar label). Details of the experiment and 
result interpretation are available in the corresponding publication.
8 
 
critical role in error free TLS of the dG-C8-IQ (1.26) lesion.
8
 
The structure of dG-C8-IQ (1.26) at each guanine site in the NarI recognition site in the 
duplex has also been reported. At the G1 and G2 positions of the NarI site, dG-C8-IQ (1.26) is 
located in the minor groove and at the G3 position dG-C8-IQ (1.26) is intercalated, and the 
adduct was found to be in the syn conformation.12 Overall, Pol η, κ, and ζ are the primary 
TLS polymerases implicated in the bypass of the dG-C8-IQ (1.26) adduct.
8
 The siRNA 
knockdown study also revealed that the primary mutation induced by dG-C8-IQ (1.26) in 
HEK293T cells was GT transversions, and the minor mutation was GA transitions.8 No 
frameshift mutations and no GC transversions were induced by dG-C8-IQ (1.26) in HEK293T 
cells.
8
 Furthermore, previous in vitro study showed that human pol η extended primers beyond 
dG-C8-IQ (1.26) adduct at either G1 or G3 more efficiently than pol κ or pol ι (η > κ > ι).
4
 This 
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study also established that pol η is capable of the misinsertion of dATP opposite the dG-C8-IQ 
(1.26) adduct, but could not extend from dG-C8-IQ:A base pair, and that pol ι is capable of the 
misinsertion of dTTP, but not extension from the dG-C8-IQ:T base pair.
4
 Further extension after 
the misinsertion of dATP by η as demonstrated in the in vitro study, would yield the GT 
transversion observed in HEK293T cells.
4, 8
 Similarly, pol ι is capable of misinserting dTTP, 
which would yield the GA transition observed in HEK293T cells upon further extension.4, 8 
However, the in vitro study implicates pol η and ι are incapable of extending from the respective 
mismatch base they insert opposite of the dG-C8-IQ (1.26) lesion.
4
 The current study 
investigates the in vitro TLS polymerases involved in extending from the mismatched base pairs, 
dG-C8-IQ:A and dG-C8-IQ:T, that will yield the GT transversion and the GA transitions 
observed in HEK293T cells.  We were particularly interested in the potential roles of pols κ and 
ζ, which were found to be most responsible for mutagenic TLS of dG-C8-IQ (1.26). 
 
Results and Discussion 
TLS by Pol ζ and Rev1 
In the previous bypass study, no in vitro TLS experiment using pol ζ or Rev1 were 
conducted. In the current study, the bypass dG-C8-IQ (1.26) at G1 and G3 in the NarI restriction 
site with these specialized pols was evaluated. A 5ʹ-32P-labeled 19mer or 22mer (-1) primer was 
annealed to appropriate complementary template strand containing the dG-C8-IQ (1.26) adduct 
(0-position) (Figure 2-03). Primer extension assays were performed with pol ζ in the presence of 
all four deoxyribonucleotide triphosphates (dNTPs) to determine the capability of pol ζ to 
perform TLS of dG-C8-IQ (1.26). The primer extension was performed with Rev1 in the 
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presence of dCTP.  Yeast pol ζ (ypol ζ) and Rev1 (Figure 2-04) were unable to incorporate a 
nucleotides opposite dG-C8-IQ (1.26) at either G1 or G3. The lack of nucleotide insertion by ypol  
 
Figure 2-03: Duplexes utilized in TLS assays 
 
ζ and Rev1 opposite of the dG-C8-IQ (1.26) adduct is consistent with the reported roles of the 
polymerases. The primary role of pol ζ in TLS is reportedly performing extension following 
insertion opposite of the lesion by another TLS polymerase.
13
 In addition, Rev1 is reported to 
proficiently incorporate a dC opposite of various N
2
-adducted dGs, otherwise Rev1 acts 
frequently as an accessory protein.
9, 14
 As pol ζ typically acts as an extender, the role of ypol ζ to 
extend from a dG-C8-IQ:N template-primer junction was evaluated (Figure 2-05). Indeed, ypol ζ 
was observed to extend from dG-C8-IQ:N base pairs at G1 and G3, where N is C, A or T, by at 
least one nucleotide. The three primers represent the major replication outcomes observed in the 
cell mutagenesis studies. Interestingly at G3, further extension of three nucleotides beyond the 
lesion was ∼4-fold more efficient (22% versus 5%) for the dG-C8-IQ:A pair than dG-C8-IQ:C  
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Figure 2-04: In vitro insertion and extension assay of the dG-C8-IQ adduct by ypol ζ and human Rev1 insertion 
assay. (A) Insertion by pol ζ of dCTP opposite a control unmodified dG (left) and reaction of the dG3-C8-IQ 
modified oligonucleotide in the presence of all four dNTPs. (B) Insertion of dCTP (100 μM) opposite a control C 
(left) or dG1-C8-IQ (right) by hRev1 at 37 °C. (C) Insertion of dCTP opposite a control unmodified dG (left) and 
reaction of the dG1-C8-IQ modified oligonucleotide in the presence of all four dNTPs. (D) Insertion of dCTP (100 
μM) opposite a control C (left) or dG1-C8-IQ (right) by hRev1 at 37 °C. The DNA concentration was 10 nM.  
 
pair, implying pol ζ's critical role in error-prone TLS of dG-C8-IQ (1.26) (figure 2-05A). 
Extension of the dG3-C8-IQ:T pair by three or more bases was modest (< 2%). At the dG1-C8-
IQ:N primer terminus, where N is C, A or T, ypol ζ does not extend beyond the insertion of one 
nucleotide (Figure 2-05B). Extension by one nucleotide from dG1-C8-IQ:C primer terminus was 
more efficient than for the mismatch pair with A or T. However, ypol ζ is capable of extension 
from the mispairs, dG1-C8-IQ:A and dG1-C8-IQ:T (Figure 2-05B). Extension beyond the one 
nucleotide inserted by ypol ζ at (Figure 2-05B). Extension beyond the one nucleotide inserted by 
ypol ζ at the dG1-C8-IQ:N terminus would require the cooperation of another TLS polymerase. 
Individually, pol ζ and pol κ are implicated in error-prone TLS of dG-C8-IQ (1.26) through the  
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Figure 2-05: In vitro extension assay of the dG-C8-IQ adduct by ypol ζ. (A) Extension of the dG3-C8-IQ adduct 
when paired with C, A, or T after 5h at 37
0
C. (B) Extension of the dG1-C8-IQ adduct when paired with C, A, or T 
after 5h at 37
0
C. The DNA was 10 nM. 
 
reduction in MF upon siRNA knockdown of the enzyme in cellular studies.
8
 The in vitro 
extension from mispairs at G3 and G1 with dG-C8-IQ (1.26) by ypol ζ is in agreement with the 
cellular results. However, the incomplete extension of the primer in the in vitro assay implies 
cooperation of an additional polymerase is required. The cellular assays imply pol ζ and pol κ 
cooperatively perform this error prone TLS as the MF is reduced to less than 5% upon double 
knockdown of pol ζ and pol κ.8  
 
TLS by Pol κ 
In the previous in vitro study, human pol κ was capable of inserting dCTP or dGTP 
opposite of the dG-C8-IQ (1.26) adduct, but did not extend.
4
 Base substitution mutations 
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resulting from the misinsertion of G are not observed in cellular assays.
8
 Therefore, misinsertion 
does not account for the role of pol κ in error prone TLS indicated by the results of the cellular 
assays described above. Various in vitro assays with human pol κ are reported here to elucidate 
the role of pol κ in the error-prone TLS of dG-C8-IQ (1.26) at G1 and G3 of the of the NarI 
restriction site.   Extension of the dG3-C8-IQ:N pair was observed for pol κ, where N is A or T 
but not C, but only at a high protein concentration (Figure 2-06A). Extension of three or more 
nucleotides past the lesion site was ∼8 and 5% for N = A and T, respectively. Interestingly, 
intermediate extension products for pol κ were in lower abundance than for the ypol ζ extension. 
This suggests insertion of the first nucleotide past the dG3-C8-IQ:N pair (+1 position) may be 
rate limiting for pol κ. Extension of the dG1-C8-IQ:N pair was observed for pol κ, where N is A 
or but not C or T, but only at a high protein concentration (figure 2-06B). Extension of two or 
more nucleotides past the lesion site was ∼24% for N = A. The low activity of pol κ in this in 
vitro assay would indicate pol κ has a minor role in error-prone TLS. However, in the cellular 
assay pol κ contributed more to error-prone TLS than any other individual TLS polymerase 
evaluated.
8
 The cellular studies indicated cooperativity between pol ζ and pol κ. In our in vitro 
results, ypol ζ extended from the mismatch dG-C8-IQ:N, where N is A or T, primer terminus by 
at least 1 base pair, and the observation was made that further extension would require 
cooperation of an additional polymerase, most likely pol κ. Thus, the next assay reported 
examines pol κ's ability to extend a C:G template-primer (+1 primer) terminus containing the 
dG-C8-IQ:N pair (at the 0-position) at either G3 or G1. Pol κ efficiently extended the primer 
when N was C and A while extension of the primer containing the dG-C8-IQ:T pair was modest 
at both G3 and G1 (figure 2-06C and D). This suggests that pol κ can extend the primer after 
another TLS pol inserts nucleotides opposite the lesion and its 5′ base. The previous in vitro  
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Figure 2-06: (A) Extension past a dG3-C8-IQ:N pair (N = C, A and T; 10 nM). (B) Extension past a dG1-C8-IQ:N 
pair (N = C, A and T; 10 nM) . (C) Primer extension of a G:C primer template terminus (+1 position) and dG3-C8-
IQ:N pair (N = C, A and T; 0-position). (D) Primer extension of a G:C primer template terminus (+1 position) and 
dG1-C8-IQ:N pair (N = C, A and T; 0-position). The DNA concentration was 10 nM and was extended by human 
pol κ after 5 h at 37°C in the presence of all four dNTPs (100 μM). 
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insertion of the 5ʹ-base from the mispaired, dG-C8-IQ:A or dG-C8-IQ:T, primer terminus and 
further extension by κ. Pol κ is reported to be a proficient extender of mispaired termini.9, 15 The 
above in vitro assay indicates that in the case of mispairs with dG-C8-IQ (1.26), pol κ requires 
the cooperation of additional TLS polymerases. 
 
TLS by Pol ι 
 Cellular studies indicate pol ι plays a minor role in error-prone TLS of dG-C8-IQ (1.26) 
with MF slightly decreasing upon knockdown.
8
 In the previous in vitro study, human pol ι was 
less efficient than pol η and κ. Pol ι was capable of inserting C or T opposite of the lesion, then 
no further extension was observed.4 The previous in vitro study indicates that the misinsertion of  
 
Figure 2-07: In vitro extension assay of the dG-C8-IQ adduct by pol ι. (A) Extension of the dG3-C8-IQ adduct 
when paired with C, A, or T after 5h at 37
0
C. (B) Extension of the dG1-C8-IQ adduct when paired with C, A, or T 
after 5h at 37
0
C. The DNA was 10 nM. 
 55 
 
T is one way pol ι contributes to error-prone TLS. The ability of pol ι to extend in vitro from dG- 
C8-IQ mismatched primer termini at G1 and G3 of the NarI sequence was evaluated (Figure 2- 
07). Human pol ι did not extend from the dG3-C8-IQ:N, where N is C, A, or T, primer termini in 
vitro (Figure 2-07A). In fact, the only extension observed for pol ι was modest extension of the 
dG1-C8-IQ:A mispair by up to two nucleotides with ~28% extension beyond the zero primer 
(Figure 2-07B). These results agree with the conclusion of the previous work that pol ι has a 
minor role in the TLS of the dG-C8-IQ (1.26) adduct.4, 8 The differential processing of the dG- 
C8-IQ (1.26) adduct at G1 vs G3 of the NarI site may be related to the differences in structure 
within the duplex, where the adduct is located in the minor groove at G1 but intercalated at G3.
12
 
 
TLS by Pol η 
 Previous in vitro studies and cellular studies agree that Pol η is primarily responsible for 
error-free TLS of dG-C8-IQ (1.26) lesions.
4, 8
 The siRNA knockdown of pol η increased the MF 
at guanine in the NarI sequence, including a 26% increase in MF at G3. The conclusion drawn 
from the result was that pol η is key in error-free TLS of dG-C8-IQ (1.26). However, the results 
do not preclude pol η from a minor role in error-prone TLS. In fact, pol η was the only enzyme 
observed to misinsert A opposite of dG-C8-IQ (1.26) in the previous in vitro study. This would 
suggest that pol η also has a role in generating the primary mutation observed in cellular studies, 
GT transversions. However, in the previous in vitro study, pol η was not capable of extending 
from the mispaired dG-C8-IQ:A terminus. TLS by pol η was examined from the primer terminus 
dG-C8-IQ:N, where N is C, A, or T to further elucidate the polymerases role in TLS of dG-C8-
IQ (1.26) (Figure 2-08). At G3, pol η was ∼2-fold more efficient in extending from the dG-C8- 
IQ:C pair than from the mispairs with A or T (46% versus 28 and 21%), thus the correct  
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Figure 2-08: In vitro extension assay of the dG-C8-IQ adduct by pol ι. (A) Extension of the dG3-C8-IQ adduct 
when paired with C, A, or T after 5h at 37
0
C. (B) Extension of the dG1-C8-IQ adduct when paired with C, A, or T 
after 5h at 37
0
C. The DNA was 10 nM. 
 
extension from the dG3-C8-IQ:N, where N is C, A, or T, primer terminus. Pol η was observed to 
extend from dG1-C8-IQ:N primer terminus, where N is C, A or T, to more than full length 
(Figure 2-08B). Interestingly, the extension from the dG1-C8-IQ:C was not favored over 
extension from the mispair of A or T with the adduct at G1, which contradicts the cellular results. 
Extension from dG-C8-IQ:A was observed as 71%  at full length versus extension from T or C at 
43% or 38% respectively. These results suggests pol η also contributes to the GT transversions 
and the GA transitions observed in cellular studies.8 Pol η extended from dG1-C8-IQ 
mispaired with either A or T.  The results for the in vitro extension by pol η of dG3-C8-IQ:N, 
where N is C, A, or T, were in agreement with previous in vitro insertion and extension results 
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and cellular results, which indicated pol η primarily yielded error-free TLS of dG3-C8-IQ:C for 
the adduct at G3. The disagreement between in vitro and cellular studies when dG-C8-IQ (1.26) 
is at G1 of the NarI sequence may be due to the differences in environment and the accessory 
proteins present in cells to assist in TLS. Overall, the previous and current results indicate pol η 
may contributed to base substitution mutations through the insertion of dATP opposite of the dG-
C8-IQ (1.26) adduct and through extension from the primer terminus dG-C8-IQ:N, where N is A 
or T.  
 
Summary: the Role of TLS Polymerases Contributing to dG-C8-IQ Mutagenesis     
Bulky DNA adducts such as dG-C8-IQ (1.26) are known to block DNA replication. The 
C8 and N
2
-IQ adducts of dG are a strong block to in vitro TLS by pol δ.4 In addition, the 
carbocyclic anaolog of dG-C8-IQ (1.26) inhibited replication by E. coli DNA polymerase I, exo-
free Klenow fragment, exo-free DNA polymerase II, and Dpo4.
16
 Previously, human pol η was 
the only pol identified to efficiently extend primers beyond the dG-C8-IQ (1.26) adduct site in 
vitro, where pol κ and ι were shown to insert opposite the lesion followed by little to no 
extension.
16
  
In recent studies, TLS pols ζ, Rev1, κ, ι, and η are implicated in the TLS of the C8-dG 
lesion of the probable carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) through siRNA 
knockdown of the TLS pols in HEK293T cells.
17
,
8
 However, TLS was not wholly dependent 
upon anyone polymerase as was the case for the C8-dG adduct of 3-nitrobenzanthrone (dG-C8-
ABA).
18
 The TLS of the dG-C8-IQ (1.26) lesion was examined at each guanine in the NarI 
recognition sequence, a hotspot for frameshift mutations, where the dG-C8-IQ (1.26) lesion is 
known to be intercalated at G3 and located in the minor groove at G2 and G1.
12
 The efficiency of 
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TLS pols in processing the dG-C8-IQ (1.26) lesion and the mutagenicity at the respective 
adducted guanine were the only clear discrepancies between the locations of the lesion in the 
NarI site.
8
 The percentage of TLS and the level of mutagenicity were observed as G3 > G2 > G1.
8
 
The variance in the efficiency of TLS and mutagenicity observed in HEK293T cells may be due 
to the difference in structure between the adduct located at G3 vs G2 and G1. It is possible that 
large active sites of TLS pols accommodate various conformations of a DNA adduct in their 
active site involving both Watson−Crick and non-Watson−Crick hydrogen bonding to bypass 
bulky lesions.  
In cellular studies dG-C8-IQ (1.26) induced primarily G→T transversions and a minority of 
G→A transitions in HEK293T cells; importantly, no frameshift mutations were observed.8 
siRNA knockdown studies suggest that pol η is essential for the error-free bypass of the dG-C8-
IQ (1.26) lesion in HEK293T cells, while pol κ and ζ were observed to be the primary 
polymerases involved in error-prone TLS. Thus, pols ζ and κ are implicated in the generation of 
the observed base substitution mutations in the cellular study in HEK293T cells.
8
 Pol η and ι 
were previously related to the observed mutations through the observation that pol η will insert 
dATP and pol ι will insert dTTP opposite of the dG-C8-IQ (1.26) in vitro. However, when 
misinsertion occurred, pol η and ι did not extend from the misinserted base.4 Therefore, the 
polymerases responsible for extending the dG-C8-IQ (1.26) mispaired primer termini were 
unknown. The role of TLS polymerases ζ, Rev1, κ, ι, and η in contributing to the G→T 
transversions and G→A transitions were further examined through in vitro extension from the 
primer terminus dG-C8-IQ:N, where N is C, A, or T at both the G1 and the iterated G3 position of 
the NarI site. Pol ζ and Rev1 were also evaluated for the ability to insert nucleotides opposite of 
the dG-C8-IQ (1.26) lesion, and were found incapable of insertion, in vitro (Figure 2-04). The 
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lack of insertion by pol ζ is consistent with reports that pol ζ acts primarily as an extender.19, 20 In 
the in vitro assay, pol ζ was observed to extend ~4 fold more efficiently from A vs C at G3, 
which is consistent with role in error-prone TLS implied by the study HEK293T cells (figure 2-
05).
8
 Interestingly, pol κ was very inefficient at extending from the dG-C8-IQ:N, where N is C, 
A, or T, primer terminus at either G3 or G1 (figure 2-06A and B). Minimal extension by pol κ 
from A and T was observed at G3 as well as from A at G1. Insertion of the nucleotide after the 
adduct (+1 primer position) was suspected to be rate limiting for pol κ. Pol κ was then shown to 
extend relatively efficiently from the +1 primer position after the dG-C8-IQ:A mispair (Figure 2-
06C and D). The result suggests the cooperation of additional polymerases to participate in error-
prone TLS of dG-C8-IQ (1.26). This is consistent with the cellular assay, which observed a 
synergistic decrease in MF upon double knockdown of pols κ and ζ.8 In the in vitro assay, pol η 
was observed to participate more efficiently in error-free TLS at G3 but not at G1. The results for 
in vitro TLS by pol η at G1 represent a significant discrepancy in comparison to the cellular study 
where and increase in MF at G1 was observed upon knockdown.
8
 This discrepancy may be due 
to difference in environment in cellular studies compared to in vitro and to the presence of 
accessory proteins participating in TLS in cells. Our results for pol ι, where minimal extension 
from dG1-C8-IQ:A was observed, were consistent with pol ι playing a minor role in TLS of dG-
C8-IQ (1.26) as suggested by the cellular study. In the in vitro assays, there was at least some 
extension from dG-C8-IQ:N, where N is A or T, by TLS pols ζ and η, as well as, extension by 
pol κ from mispairs from the +1 position, 5' to the lesion. Overall, the in vitro assay indicates that 
each pol investigated has at least some participation in error-prone TLS, which is consistent 
cellular study.
8
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Figure 2-09: Primary results for the TLS of dG-C8-IQ. 
The results of the previous and current in vitro TLS assays in combination with the 
cellular assay in HEK293T cells suggest the primary mutation observed G→T transversions arise 
from the misinsertion of A opposite of dG-C8-IQ (1.26) by pol η followed by the cooperative 
extension from the lesion site by pols ζ and κ (Figure 2-09). The compiled data also indicates the 
minor mutation, G→A transitions, observed results from misinsertion of T opposite of dG-C8-IQ 
(1.26) by pol ι followed by the cooperative extension by pols ζ and κ (Figure 2-09). In general, in 
vitro assays suggest extension from T is less efficient than extension from A and is likely the 
reason G→T transversions are predominating. 
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Experimental Procedures 
Materials. yPol ζ, hPol κ, and hpol ι were purchased from Enzymax (Lexington, KY). 
hRev1 was either a gift from the laboratory of F. P. Geungerich (Vanderbilt University, 
Nashville, Tn) or purchased from Enzymax (Lexington, KY). The catalytic core of hPol η was a 
gift from the laboratory of Martin Egli at Vanderbilt University (Nashville, TN). The dNTP 
solutions (100 mM) were purchased from New England Biolabs (Ipswich, MA) or GE 
Healthcare (formerly Amersham Biosciences, Piscataway, NJ). [γ-32P]ATP was purchased from 
Perkin Elmer (Waltham, MA). dG-C8-IQ (1.26) modified oligonucleotides were prepared as 
previously reported.
4
 Unmodified oligonucleotides were purchased from Midland Certified 
Reagents (Midland, TX). 
Labeling and Annealing of Oligonucleotides. The primer was 5´ end-labeled with [γ-
32
P]ATP using T4 polynucleotide kinase (New England Biolabs, Ipswich, MA) according to the 
manufacturer’s instructions and purified on a Biospin column (BioRad, Hercules, CA). Each 
template and the respective 
32
P-labeled primer (1:1 molar ratio) were annealed in Tris-HCl buffer 
(50 mM, pH 7.5) by heating at 90 °C for 5 min and then slowly cooling to room temperature (r. 
t.) in accordance with previously published procedure.
4
   
 Single-Nucleotide Incorporation Assays. 
32
P-labeled primers were annealed to either 
the unmodified or the dG-C8-IQ (1.26) modified template, and extension reactions were then 
carried out in the presence of single dNTPs. All reactions were initiated by the addition of the 
dNTP solution (100 µM) to preincubated enzyme/DNA mixtures giving a final reaction volume 
of 20 µL. The final concentrations of the components for the incorporation assays were in Tris-
HCl (50 mM, pH 7.5), DNA duplex (10 nM), ypol ζ (2.5, 5, or 10 nM) or Rev1 (2.5, 5, or 10 
nM), dithiothreitol (DTT, 5 mM), bovine serum albumin (BSA, 50 µg/mL-1), NaCl (50 mM), 
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and MgCl2 (5 mM). The ypol ζ reactions were run at 37 °C for 2 hr. Reactions were quenched 
with equal volume of EDTA (20 µL, 20 mM) in 95% formamide (v/v) containing xylene cyanol 
and bromophenol blue dyes. Aliquots (20 µL) were separated by electrophoresis on a denaturing 
gel containing urea (8.0 M) and 16 % acrylamide (w/v) (from a 19:1 acrylamide/bisacrylamide 
solution, AccuGel, National Diagnostics, Atlanta, GA) with Tris borate buffer (80 mM, pH 7.8) 
containing EDTA (1 mM). The gel was exposed to a PhosphorImager screen (Imaging Screen K, 
Bio-Rad) overnight. The bands were visualized with a PhosphorImaging system (Bio-Rad, 
Molecular Imager FX) using the manufacturer’s Quantity One software, version 4.3.0. 
Full-Length Extension Assay with All Four dNTPs. The unmodified or dG-C8-IQ 
(1.26) modified template was annealed to the 
32
P-labeled 0-primers (with a 3’-C, A, or T) or +1-
primer and extended in the presence of all four dNTPs (100 µM each) at 37 °C.  Reactions time 
were 5 hr for pols ζ and κ, and 30 min for pol ι and the catalytic core of hpol η. Each reaction 
was initiated by adding the mixture of the dNTP solution to a preincubated enzyme/DNA 
mixtures in Tris-HCl (50 mM, pH 7.5) buffer containing DNA duplex (10 nM), ypol ζ (0.2, 0.4, 
1.0, 2, and 3.3 nM), hPol κ 0-primer (2.0, 3.3, 5.0, 10, 30 nM), hPol κ +1-primer (0.2, 0.4, 1.0, 2, 
and 3.3 nM), hpol ι (0.2, 0.4, 1.0, 2, and 3.3 nM), or hpol η (0.2, 0.4, 1.0, 2, and 3.3 nM), DTT (5 
mM), BSA (50 µg/mL), NaCl (50 mM), and MgCl2 (5 mM), giving a final reaction volume of 20 
µL. Reactions were quenched by the addition of equal volume of EDTA (20 mM) in 95% 
formamide (v/v) containing xylene cyanol and bromophenol blue dyes. Aliquots (20 µL) were 
separated by electrophoresis on a denaturing gel containing urea (8.0 M) and 16 % acrylamide 
(w/v) (from a 19:1 acrylamide/bisacrylamide solution, AccuGel, National Diagnostics, Atlanta, 
GA) with Tris borate buffer (80 mM, pH 7.8), containing EDTA (1 mM). Gels were exposed to a 
PhosphorImager screen (Imaging Screen K, Bio-Rad) overnight. The bands were visualized with 
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a PhosphorImaging system (Bio-Rad, Molecular Imager FX) using the manufacturer’s Quantity 
One software, version 4.3.0. 
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CHAPTER III 
 
REPLICATION OF THE N
2
-DEOXYGUANOSINE IQ ADDUCT 
 
Introduction 
TLS across Bulky N
2
-alkyl Guanine DNA Adducts by Pol δ, ι, η, and κ 
A series of studies have examined the TLS of several bulky N
2
-alkyl guanine DNA 
adducts.
1, 2, 3
 The results may lend insight into the TLS of dG-N
2
-IQ (1.27) adduct which was 
shown to undergo slower repair than dG-C8-IQ (1.26) and contributes to carcinogenesis induced 
by IQ in laboratory animals.
4, 5, 6
 A set of seven N
2
-alkyl or aryl adducts ranging in size from the 
smallest N
2
-methyl-dG (N
2
-Me-dG) to the largest N
2
-methyl(6-benzo[a]pyrenyl)-dG (N
2
-BPdG) 
were evaluated for the effect of their bulk on TLS by DNA pols δ, ι, η, and κ.1, 2, 3 Pol δ with 
PCNA was the most affected by adduct size. Pol δ/PCNA was hindered from bypassing lesions 
larger than N
2
-Me-dG and N
2
-ethyl-dG (N
2
-Et-dG), which were bypassed in an error free 
manner. Pol ι, η, and κ were able to bypass lesions smaller than N2-methyl(2-naphthyl)-dG (N2-
Naph-dG), where pol ι bypass was error prone pols η and κ bypass were primarily error-free. 
Error-prone bypass by pol ι is probably related to the polymerase bypass utilizing Hoogsteen 
base pairing.
2, 3 Pol η and κ were the only polymerases active in vitro for the bypass of adduct 
larger than N
2
-methyl(9-anthracenyl)-dG (N
2
-Anth-dG). However, with the larger adduct size pol 
η bypass was primarily error-prone, while pol κ bypass was relatively error-free.1, 2, 3 Overall, the 
authors of the study concluded that pol κ may be considered the most efficient and accurate TLS 
pol for bypass of bulky N
2
-guanine minor groove DNA adducts. In making comparisons to the 
above study, there are key differences that should be noted.
1, 2, 3
 The alkyl and aryl alkyl N
2
-
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guanine adducts considered in the above study are more hydrophobic than our aryl amine of 
interest dG- N
2
-IQ. In addition, the structure of dG-N
2
-IQ (1.27) at G1 and G3 of the NarI 
recognition site, (5ʹ-G1G2CG3CC-3ʹ), has been reported and the lesion was intercalated and in the 
anti-conformation at both positions, not in the minor groove.
7, 8
 The anti-conformation of the dG-
N
2
-IQ (1.27) about the gylcosyl bond precludes the possibility of Hoogsteen base pairing unless 
the polymerase instigates conformational changes.  
 
TLS: Incorporation of Nucleotides Opposite of dG-N
2
-IQ 
The N
2
 deoxyguanosine adduct of IQ is less prevalent than the C8-adduct in reaction with 
DNA. However, the dG-N
2
-IQ (1.27) adduct accumulates in vivo due to slower repair.
4, 5, 6 
The in 
vitro replication of the dG-IQ adducts has been investigated previously. The IQ lesions were site 
specifically incorporated into 27mer templates at the G1 and G3 positions of the NarI recognition 
site.
6
 As discussed in Chapter 1, sequences with GC dinucleotide repeats are susceptible to 
frameshift mutations. As a result, these sequences are of interest to determine if the DNA 
adducts of interest are capable of inducing frameshift mutations. For example, the replication of 
the dG-AAF adduct, especially when located at the iterated G3 positon (5ʹ-G1G2CG3CC-3ʹ), is 
susceptible to frameshift mutations in E. coli.
9, 10, 11
 The in vitro  replication of dG-N
2
-AAF in a 
non-dinucleotide repeat sequence by pol η resulted in a small number of frameshift mutations.12 
However, dG-C8-AAF and dG-N
2
-AAF induce only base substitutions in simian (human 
embryonic) kidney cells.
9, 10, 11, 12
 The previous studies revealed the ability of TLS polymerases 
η, κ, ι and the B-family polymerase δ/PCNA to incorporate nucleotides opposite of and past both 
the dG-C8-IQ (1.26) and dG-N
2
-IQ (1.27) lesions. Replication by pol δ is completely blocked by 
the IQ adducts. When present in the NarI restriction site, human pol η extended primers beyond 
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dG-N
2
-IQ (1.27) more efficiently than pol κ and much better than pol ι.6 TLS of the dG-N2-IQ 
(1.27) lesion at the iterated G3 position by pol η resulted in –2 deletion products identified by 
liquid chromatography/mass spectrometry (LC/MS). At the G1 position, insertion and extension 
by pol η was observed up to 4 bases utilizing 32P-labeled primers separated by gel 
electrophoresis to visualize extension. However, the analysis of extension products by LC/MS 
primarily yielded primer where dCTP was inserted opposite of the dG-N
2
-IQ (1.27) with no 
further extension beyond dG-N
2
-IQ:C. Pol η was observed to insert dCTP and dATP opposite of 
the dG-N
2
-IQ (1.27) lesion, and the misinsertion frequency of dATP by pol η was 0.71 at G1 and 
0.042 at G3. However, no extension was observed, when pol η inserted dATP opposite of the 
lesion.
6
 Human pol κ was capable of inserting dCTP and dGTP opposite of the dG-N2-IQ (1.27) 
adduct, then extension of a few base pairs was observed but not to full-length.
6
 The misinsertion 
frequency of dGTP by pol κ was .0023 at G1 and .047 at G3. The same study revealed human pol 
ι would insert dCTP or dTTP opposite of dG-N2-IQ (1.27) lesion.6 Pol ι was incapable of further 
extension following insertion, and the reported misinsertion frequency of dTTP was 0.56 at G1 
and 0.33 at G3.
6
  Of the polymerases examined, the pol η was the most efficient in the insertion 
of dCTP opposite of dG-N
2
-IQ (1.27) in vitro. The misincorporation results of this in vitro study 
suggested that TLS of dG-N
2
-IQ (1.27) could result in GA transitions, or the transversions 
GT, GC.6 Further studies in HEK93T cells would reveal that mutations observed in 
HEK293T cells from replication of dG-N
2
-IQ (1.27) were GA and GT point mutations.13 
Thus, the in vitro insertion of dGTP by pol κ was irrelevant to the mutagenesis induced by the  
lesion. 
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Induced Mutagenesis siRNA knockdown of TLS Polymerases 
The mutagenesis of the dG-N
2
-IQ (1.27) adduct in HEK293T (human embryonic) kidney 
cells was investigated utilizing siRNA knockdown of the TLS polymerases. The study was 
performed in the laboratory of Ashis K. Basu. This study specifically investigated the role of 
various TLS polymerases η, κ, ι, ζ, and hRev1 in bypassing dG-N2-IQ (1.27) located at the three 
guanine positions of the NarI restriction site in human cells.
13
 In this particular investigation, the 
siRNA knockdown of the targeted TLS polymerase(s) resulted in at least 70% silencing. The 
negative control, where TLS was not reduced, revealed that the percentage of TLS of dG-N
2
-IQ 
(1.27) was greater G1 versus G2 or G3, G1 > G2 > G3 (Figure 3-01). Each of the TLS pols the 
reduction in the %TLS relative to wild-type (WT) for each knockdown performed (Figure 3-01). 
The simultaneous knockdown of pol η/pol ζ/hRev1 showed the most pronounced effect on  
 
Figure 3-01. The effect of the siRNA knockdowns of TLS polymerases on the percentage of replicative bypass of 
the dG-N
2
-IQ at G1, G2 and G3 of the oligonucleotide constructs in HEK293T cells. The cells were transfected 
with NC siRNA (WT) or siRNA for single, double or triple pol(s) knockdowns (according to each bar label). 
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reduction in TLS indicating significant involvement of these polymerases in processing the dG-
N
2
-IQ (1.27) lesion. Considering the individual knockdown of the polymerases, reduction in TLS 
evaluated were involved in replication of dG-N
2
-IQ (1.27) adduct to some extent as indicated by 
was nearly equivalent upon knockdown of η, ζ, ι, or hRev1, which suggests that multiple 
polymerases can process the lesion or that two or more polymerases act cooperatively to bypass 
the lesion. Of the pols analyzed, the knockdown of pol κ stands out as the observed reduction in 
TLS was much less than for the other polymerases. The primary mutations observed were GT 
transversions resulting from the misinsertion of A; however, some GA transitions were also 
seen. In contradiction to the in vitro analysis, no frameshift mutations were observed. The 
analysis also showed that dG-N
2
-IQ (1.27) is mutagenic in HEK293T cells at all three sites 
(Figure 3-02). The order of mutational frequency (MF) for each adducted G was G1 > G2 > G3. 
Thus, the greatest number of mutations are observed at G1, where the highest percentage of TLS 
occurs. Knockdown of pol κ resulted in an increase in MF, which was most pronounced at G1 
(Figure 3-02). Therefore, pol κ is essential to error free bypass of the dG-N2-IQ (1.27) lesion as 
there are fewer mutations during TLS by active pol κ. In contrast, MF at each site was decreased 
when pol κ, ι, ζ or Rev1 were knocked down (Figure 3-02). Thus, these polymerases are 
collectively responsible for the error-prone TLS of dG-N
2
-IQ (1.27). The most pronounced 
decrease in MF at each site was observed upon knockdown of pol η especially at G1 and G3. In 
addition, the simultaneous knockdown of two polymerases showed that the lack of each two or 
three pol combination resulted in further decrease in MF indicating a more error prone process. 
For example, a decrease in MF was observed when pols κ and ζ were simultaneously knocked 
down (Figures 3-02), where the individual polymerases exhibited opposite effects. In addition, 
the simultaneous knockdown of pol ζ and Rev1 together, and that of pol κ, ζ, and Rev1 together,  
 72 
 
Figure 3-02. The depicted results represent the mutational frequency resulting from TLS of dG-N
2
-IQ at G1, G2 and 
G3 of the oligonucleotide constructs in HEK293T cells where the cells were transfected with NC siRNA (WT) or 
siRNA for single, double or triple pol(s) knockdowns (according to each bar label).  
 
decreased MF at each adducted guanine in the sequence much more than any one pol 
individually (Figure 3-02). Simultaneous knockdown of pols η/ζ/hRev1 exhibited a remarkable 
synergy on the reduction of MF, which indicates that the polymerases may cooperate in 
processing dG-N
2
-IQ (1.27) lesion (Figure 3-02). The results of this study suggest the most 
critical role in the error-prone TLS of the dG-N
2
-IQ (1.27) adduct is played by pols η, ζ, and 
hRev1, whereas pol ι likely has a relatively minor role in error-prone TLS of the N2 adduct. The 
study also indicates that pol κ plays a critical role in error-free TLS of the dG-N2-IQ (1.27) 
lesion.  
 Overall, Pol κ, η, hRev1, and ζ are the primary TLS polymerases implicated in the bypass 
of the dG-N
2
-IQ (1.27) adduct.
13
 The siRNA knockdown study also revealed that the primary 
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mutations induced by dG-N
2
-IQ (1.27) in HEK293T cells were GT transversions, and the 
minor mutation were GA transitions. No frameshift mutations and no GC transversions 
were induced by dG-N
2
-IQ (1.27) in HEK293T cells.
13
 Furthermore, a previous in vitro study 
showed that human pol κ and η extended primers beyond dG-N2-IQ (1.27) adduct at either G1 or 
G3.
6
 This study also established that pol η is capable of the misinsertion of dATP but not 
extension from dG-N
2
-IQ:A base pair, and that pol ι is capable of the misinsertion of dTTP, but 
not extension from the dG-N
2
-IQ:T base pair.
6
 Extension from the reported misinsertion of A by 
pol η would yield the GT transversions observed in HEK293T cells.6, 13 Extension from the 
misinsertion of T by pol ι would yield the GA transitions observed in HEK293T cells.6, 13 
However, the in vitro study suggests that pol η and ι are incapable of extending from the 
respective mismatch base they insert opposite of the dG-N
2
-IQ (1.27) lesion.
6
 The current study 
investigates the in vitro TLS polymerases involved in extending from the mismatched base pairs, 
dG-N
2
-IQ:A and dG-N
2
-IQ:T, that will yield the GT transversions and the GA transitions 
observed in HEK293T cells. 
 
Results and Discussion 
TLS by Pol ζ and Rev1 
In the previous bypass study, no in vitro TLS experiment using pol ζ or Rev1 were 
conducted. In the current study, the bypass of dG-N
2
-IQ (1.27) at G1 and G3 in the NarI 
restriction site by these specialized pols was evaluated. A 5ʹ-32P-labeled 19mer or 22mer was 
annealed to a complementary modified template containing the dG-N
2
-IQ (1.27) adduct. Primer 
extension assays were performed with pol ζ in the presence of all four dNTPs to determine the 
capability of pol ζ to perform TLS of dG-N2-IQ (1.27). The primer extension was performed with  
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Figure 3-03: Duplexes utilized in TLS assays 
Rev1 in the presence of dCTP.  Yeast pol ζ was unable to incorporate a nucleotide opposite dG-
N
2
-IQ (1.27) at G1 or G3 (Figure 3-04). hRev1 inserted dCTP opposite of dG-N
2
-IQ (1.27) at both 
G1 and G3 (Figure 3-04B and D). At G3, hRev1 inserted dCTP twice (Figure 3-04B). This may 
indicate the slippage of the template with 5ʹ neighbor C and G3-N
2
-IQ (CG3-N
2
-IQ) bulged 
outside of the duplex (Figure 3-05). In this case, with CG3-N
2
-IQ bulged outside of the duplex, 
these base would not be replicated, which would yield a −2 deletion. The lack of nucleotide 
insertion by ypol ζ is consistent with reports that the primary role of pol ζ in TLS is extension 
from lesion mispairs generated by other TLS polymerases (Figure 3-04A and C).
14
 In addition, 
insertion of dCTP opposite of dG- N
2
-IQ is consistent with reports that Rev1 proficiently 
incorporates C opposite of various N
2
-adducted dGs. Otherwise, Rev1 acts frequently as an 
accessory protein.
15, 16, 17
   
 75 
 
Figure 3-04: In vitro insertion and extension assay of the dG-N2-IQ adduct by ypol ζ and human Rev1 insertion 
assay. (A) Insertion by ypol ζ of dCTP opposite a control unmodified dG (left) and reaction of the dG3-N
2
-IQ 
modified oligonucleotide in the presence of all four dNTPs. (B) Insertion of dCTP (100 μM) opposite a control C 
(left) or dG3- N
2
-IQ (right) by hRev1 at 37 °C. (C) Insertion by ypol ζ of dCTP opposite a control unmodified dG 
(left) and reaction of the dG1-N
2
-IQ modified oligonucleotide in the presence of all four dNTPs. (D) Insertion of 
dCTP (100 μM) opposite a control C (left) or dG1- N
2
-IQ (right) by hRev1 at 37 °C. The DNA concentration was 10 
nM.  
 
As pol ζ typically acts as an extender, the role of ypol ζ to extend from a dG-N2-IQ:N  
template-primer junction was evaluated (Figure 3-06). Indeed, ypol ζ was observed to extend 
from dG-N
2
-IQ:N base pairs at G1 and G3, where N is C, A or T, by at least one nucleotide. The 
three primers represent the major replication outcomes observed in the cell mutagenesis studies. 
Interestingly, pol ζ extended from the mispair of dG-N2-IQ (1.27) with T or A more readily than 
from C at both G1 and G3. The efficiency of extension by one base is more efficient at G1 than G3, 
where one base extension was T, A (82%) > C (60%) at G1 and T (57%) > A (38%) > C (20%) at 
G3. The results are consistent with the study in HEK293T cells in that the percentage of TLS by 
pol ζ was greater at G1 than at G3 and because the TLS observed by pol ζ was more error-prone  
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Figure 3-05: Slipped template alignment yielding –2 deletion products is shown. During replication with dG-N2-IQ 
and 5ʹbase bulged out of the duplex, after the replicating polymerase inserts opposite of the base 3ʹ to the lesion, the 
polymerase next inserts opposite of G2. 
 
as in the cellular study. The in vitro results suggest extension beyond the one nucleotide by ypol 
ζ at the dG-N2-IQ:N terminus, where N is A, T, or C, would require the cooperation of another 
TLS polymerase to extend several base pairs beyond the lesion where normal replication could  
Figure 3-06: In vitro extension assay of the dG-N
2
-IQ adduct by ypol ζ. (A) Extension of the dG3- N
2
-IQ adduct 
when paired with C, A, or T after 2 h at 37 °C. (B) Extension of the dG1- N
2
-IQ adduct when paired with C, A, or T 
after 2 h at 37 °C. The DNA was 10 nM. 
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resume. The synergistic effect of the reduction in MF by the triple knockdown of pol ζ/η/ hRev1, 
also suggests cooperation of the polymerases in TLS of the N
2
-IQ lesion. The inability of pol ζ to 
insert nucleotides opposite of dG-N
2
-IQ (1.27) and the ability to extend from dG-N
2
-IQ:N, where 
N is C, A, or T, is consistent with the reported role of pol ζ as an extender from error free lesion 
and mispaired lesion termini.
15, 17, 18,
 
19,
 
20
 
 
TLS by Pol ι 
 Cellular studies indicate pol ι plays a minor role in error-prone TLS of dG-N2-IQ (1.27) 
with MF slightly decreasing upon knockdown.
13
 In the previous in vitro study, human pol ι was 
less efficient than pol η and κ. Pol ι was capable of inserting C or T opposite of the lesion, then 
no further extension was observed.
6
 The previous in vitro study indicate that the misinsertion of 
T is one way pol ι contributes to error-prone TLS. The ability of pol ι to extend in vitro from dG-
N
2
-IQ (1.27) mismatched primer termini at G1 and G3 of the NarI sequence was evaluated 
(Figure 3-07). Human pol ι extend from the dG-N2 -IQ:A primer termini by one base pair in vitro 
(Figure 3-07). The extension from G1 was ~9 times more efficient than from G3, where the 
percentage of primer extended by one base was ~90% and 10%, respectively. Pol ι failed to 
extend from dG-N
2
-IQ:N, where N is C or T, as in the previous in vitro study. These results 
agree with the conclusion of the cellular study that pol ι has a minor role in the TLS of the dG-
N
2
-IQ (1.27) adduct, also the percentage of TLS and the MF are greater at G1 than G3. TLS of the 
dG-N
2
-IQ (1.27) by pol ι was error-prone as in the case of the N2-alkyl-guanine study discussed 
above. The differential processing of the dG-N
2
-IQ (1.27) adduct at G1 versus G3 of the NarI site 
may be related to minor differences in structure where within the duplex, the base pair to G1,  C 
in the complementary strand, is rotated further out of the duplex then at G3. In addition, a slight  
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Figure 3-07: In vitro extension assay of the dG-N
2
-IQ adduct by pol ι. (A) Extension of the dG3- N
2
-IQ adduct when 
paired with C, A, or T after 30 min at 37
 
°C. (B) Extension of the dG1- N
2
-IQ adduct when paired with C, A, or T 
after 30 min at 37 °C. The DNA was 10 nM. 
 
unwinding of theduplex was observed at G1 but not at G3.
8
 The structural findings suggest the 
duplex is more distorted at G1 than G3, which may affect polymerase recognition and binding.
1
 
Considering the anti-conformation of the dG-N
2
-IQ (1.27) lesion, any replication by pol ι 
isinteresting. Pol ι known for replicating through the syn conformation of adducts, as pol ι 
utilizes Hoogsteen base pairing during replication.
2, 3, 17, 21
  
 
TLS by Pol η 
 Previous in vitro studies suggests pol η participates in error-prone TLS of dG-N2-IQ 
(1.27) lesions through the misinsertion of A opposite of dG-N
2
-IQ (1.27) and frameshift 
mutations observed as −2 deletion products when N2-IQ lesion is at G3.
6
 However, frameshift 
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mutations were not observed in HEK293T cells upon siRNA knockdown of pol η. The 
discrepancy maybe related to accessory proteins present in cells that may assist in TLS, for 
example, through preventing the adduct from bulging out of the duplex. The misinsertion of A 
opposite of the dG-N
2
-IQ (1.27) lesion and extension from the base pair would account for the 
GT transversions observed in HEK293T cells. However, in the previous in vitro products 
representing extension from dG-N
2
-IQ:A were not observed upon LC/MS sequencing of the 
extension products. Furthermore, extension from dG1-N
2
-IQ:C were not observed in the LC/MS 
sequencing analysis of extension products, yet extension was observed upon utilizing 
32
P-
labeling and gel electrophoresis techniques. The conclusion of the previous in vitro study was 
that pol η could misinsert A opposite of the lesion, but further extension was blocked.6 Pol η is 
strongly implicated in the error-prone TLS of the dG-N
2
-IQ (1.27) adduct by the reduction in MF 
observed upon siRNA knockdown. In the current, in vitro extension from dG N
2
-IQ:N, where N 
is C, A, or T, by the catalytic core of pol η is evaluated when the adduct is at G1 and G3 of the 
NarI  recognition sequence (Figure 3-08). In contrast to the previous in vitro assay, extension to 
full-length from dG-N
2
-IQ:A was observed at both G1 and G3. Pol η also extended from dG-N
2
-
IQ:T mispair to full-length. Pol η extended more efficiently from dG-N2-IQ:A than from the 
mispair with T or correct base pairing with C. At G3, the extension from dG-N
2
-IQ:C was 
observed to stall after 5 base pairs, which may indicates accumulation of –2 frame shift product 
reported in the previous study (Figure 3-08A). At G3, the extension to full-length product by pol 
η was observed to be ~41% from A, ~21% from C and ~5% from T (Figure 3-08A). At G1, the 
extension to full-length product by pol η was observed to be ~71% from A, ~12% from C and 
~67% from T (Figure 3-08B). Therefore, TLS by pol η was observed to be primarily error-prone 
and the percentage of TLS performed was higher at G1 than G3, which is in agreement with the  
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Figure 3-08: In vitro extension assay of the dG- N
2
-IQ adduct by pol ι. (A) Extension of the dG3- N
2
-IQ adduct 
when paired with C, A, or T after 30 min at 37
 
°C. (B) Extension of the dG1- N
2
-IQ adduct when paired with C, A, 
or T after 30 min at 37 °C. The DNA was 10 nM. 
 
findings of the cellular study in HEK293T cells. Error-prone TLS of dG-N
2
-IQ (1.27) by pol η 
also seems to be consistent with the findings of the N
2
-alkyl-guanine study. The study reported 
TLS of N
2
 adducts the approximate size of or larger than N
2
-Anth-dG by pol η was primarily 
error-prone. Pol η was found to be capable of extending from dG-N2-IQ (1.27) adducts mispaired 
with A and T and could therefore contribute to the GT transversions and GA transitions 
observed in HEK293T cells. The –2 deletions observed in the in vitro assays were not observed 
in HEK293T cells. The lack of frameshift mutations in cells is most likely due to cooperation of 
other TLS polymerases in bypass of the lesion. Possibly, pol η and ζ cooperate in bypass as there 
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is a synergistic reduction in MF upon double knockdown of pol η/ζ and the triple knockdown of 
pol η/ζ/Rev1.  
 
TLS by Pol κ 
In the previous in vitro study, human pol κ was capable of inserting dCTP or dGTP 
opposite of the dG-N
2
-IQ (1.27) adduct, and was observed to extend a few base pairs beyond the 
lesion but not to full-length.
6
 Base substitution mutations resulting from the misinsertion of G are 
not observed in cellular assays, therefore, misinsertion does not account for the role of pol κ in 
error prone TLS indicated by the results of the cellular assays described above. In HEK293T 
cells, the MF increased upon siRNA knockdown of pol κ indicating that pol κ is essential to 
error-free TLS of the dG-N
2
-IQ (1.27) lesion in NarI sequence. In vitro analysis of TLS by 
human pol κ is reported here to elucidate the role of pol κ in the error-free and error-prone TLS 
of dG-N
2
-IQ (1.27) at G1 and G3 of the of the NarI restriction site (Figure 3-09). Extension of the 
dG3-N
2
-IQ:N pair, where N is A or T but not C, by pol κ was observed upto 5 or more base pairs 
(Figure 3-09A). Pol κ was observed to have difficulty inserting the last two base pairs of the 
primer sequence at both G1 and G3 when paired to unmodified and modified template and is most 
likely unrelated to lesion bypass. At G3, the percentage of extension by one or more bases by pol 
κ, when pol κ is 1 nM, was observed to be ~68% from C, ~31% from A and ~30% from T 
(Figure 3-09A). At G1, the percentage of extension by one or more bases by pol κ, when pol κ is 
1 nM, was observed to be ~70% from C, ~12% from A and ~60% from T (Figure 3-09B). 
Therefore, TLS by pol κ was observed to favor error-free bypass, which is in agreement with 
cellular studies. However, a significant amount of error-prone TLS was observed in vitro as pol κ 
extended from mispairs of dG-N
2
-IQ (1.27) with both A and T. Therefore, pol κ may contribute  
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Figure 3-09: (A) Extension past a dG3- N
2
-IQ:N pair (N = C, A and T; 10 nM). (B) Extension past a dG1- N
2
-IQ:N 
pair (N = C, A and T; 10 nM). The DNA concentration was 10 nM and was extended by human pol κ after 5 h at 37 
°C in the presence of all four dNTPs (100 μM). 
 
to the GT transversions and GA transitions observed in HEK293T cells. Pol κ was found to 
be efficient and accurate in the TLS of the bulky dG-N
2
-IQ (1.27) intercalated DNA lesion. This 
finding is similar to the result of pol κ TLS of bulky N2-guanine minor groove DNA adducts.3 
 
Summary: the Role of TLS Polymerases Contributing to dG-N
2
-IQ Mutagenesis 
Bulky DNA adducts such as dG-N
2
-IQ (1.27) are known to block DNA replication. The 
C8 and N
2
-IQ adducts of dG are a strong block to in vitro TLS by pol δ as are alkyl-guanine 
adducts larger than N
2
-Et-dG.
1, 3, 6
 In addition, the aryl amine dG-N
2
-AAF inhibited replication 
by pol α and δ.12 Previously, human pol η and κ were identified to efficiently extend primers 
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beyond the dG-N
2
-IQ:C base pair in vitro, where pol ι was shown to insert opposite the lesion 
with no further extension.
6
  
In recent cellular studies, TLS pols ζ, Rev1, κ, ι, and η are implicated in the TLS of the 
dG-N
2
 lesion of the probable carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline through 
siRNA knockdown of the TLS pols in HEK293T cells. However, TLS was not wholly dependent 
on any one polymerase as was the case for the C8-dG adduct of 3-nitrobenzanthrone.
22
 The TLS 
of the dG-N
2
-IQ (1.27) lesion was examined at each guanine in the NarI recognition sequence a 
hotspot for frameshift mutations. The dG-N
2
-IQ (1.27) lesion is known to be intercalated at G3 
and G1 of the NarI sequence.
7, 8
 The efficiency of TLS pols in processing the dG-N
2
-IQ (1.27) 
lesion and the mutagenicity at the respective adducted guanine were the only clear discrepancies 
between the locations of the lesion in the NarI site. The percentage of TLS and the level of 
mutagenicity were observed to follow the order G1 > G2 > G3. The variance in the efficiency of 
TLS and mutagenicity observed in HEK293T cells may be due to the differences in structure of 
the dG-N
2
-IQ (1.27) lesion and local sequence surrounding the adduct at each guanine in the 
NarI site. It is possible that large active sites of TLS pols accommodate various conformations of 
a DNA adduct in their active site involving both Watson−Crick and non-Watson−Crick 
hydrogen bonding to bypass bulky lesions such that structure may cause minimal differences in 
TLS processing.  
In cellular studies, dG-N
2
-IQ (1.27) induced primarily G→T transversions and a minor  
amount of G→A transitions. Pol κ was observed to be essential to the error-free bypass of the 
dG-N
2
-IQ (1.27) lesion in HEK293T cells, while pol η, ζ, and hRev1 were observed to be the 
primary polymerases responsible for error-prone TLS. Thus, pols ζ and η are implicated in the 
generation of the observed base substitution mutations in the cellular study, where TLS of dG-
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N
2
-IQ (1.27) is knocked down in HEK293T cells. Pol η and ι were previously related to the 
observed mutations through their ability to insert dATP and dTTP, respectively, opposite of the 
dG-N
2
-IQ (1.27) in vitro. However, when misinsertion occurred, pol η and ι did not extend from 
the misinserted bases. Therefore, the polymerases responsible for extending from the dG-N
2
-IQ 
(1.27) mispaired primer termini were unknown. In the present investigation, the role of TLS 
polymerases ζ, Rev1, κ, ι, and η in contributing to the G→T transversions and G→A transitions 
is further examined through in vitro extension from the primer terminus dG-N
2
-IQ:N, where N is 
C, A, or T at both the G1 and the iterated G3 position of the NarI site. Pol ζ and Rev1 were also 
evaluated for the ability to insert nucleotides opposite of the dG-N
2
-IQ (1.27) lesion. yPol ζ was 
found incapable of insertion (Figure 3-04A and C), while hRev1 inserted dCTP opposite of dG-
N
2
-IQ (1.27) at G1 and G3 (Figure 3-04B and D). hRev1 insertion of dCTP opposite dG-N
2
-IQ at 
G3 was followed by a subsequent insertion of dCTP, which may indicate the template slippage 
allowing –2 deletion (Figure 3-04B and Figure 3-05). Rev1 has previously been reported to 
replicate through a variety of N
2
-guanine lesions, thus Rev1 insertion opposite dG-N
2
-IQ (1.27) 
is consistent with previous studies.
15
 The lack of insertion by pol ζ is consistent with reports that 
pol ζ acts primarily as an extender. In the in vitro assay, pol ζ extended by one base pair. The 
trend for extension was A > C > T at G1 and T > A > C at G3 (Figure 3-06). Furthermore, pol ζ 
extended more efficiently at G1, 82% of 0-primer was extended one base from A, than at G3 
where 57% 0-primer was extended one base from T. The results of the in vitro and HEK293T 
cell study both indicate pol ζ participates in error-prone TLS and that TLS is more efficient and 
error-prone at G1 than G3. Pol ι exhibited one base extension from dG-N
2
-IQ:A, which was 9 
times more efficient at G1 than G3 (Figure 3-07). Extension beyond one base pair by pol ι would 
require cooperation of other TLS polymerases. Otherwise, the results indicate pol ι plays a minor 
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role in error-prone TLS of dG-N
2
-IQ (1.27), as indicated by the lowest reduction of MF upon pol 
ι knockdown in HEK293T cells (Figure 3-02). In the previous in vitro assay, replication of dG3-
N
2
-IQ:C by pol η resulted in –2 deletion product. In the in vitro assay reported here, pol η was 
observed to stall after extension from dG3-N
2
-IQ:C  by 5 base pairs, which is indicative of a –2 
deletion (Figure 3-08A). Pol η was observed to extend the most efficiently from dG-N2-IQ:A at 
both G1 and G3 (Figure 3-08). In HEK293T cells, the double knockdown of η and ζ greatly 
reduced MF (Figure 3-02). The results of these two studies imply pol η has a significant role in 
the error-prone TLS of dG-N
2
-IQ (1.27). In HEK293T cells, knockdown of pol κ results in an 
increase in MF, which implies that pol κ is essential to error-free TLS of dG-N2-IQ (1.27) in 
HEK293T cells. In our in vitro assay, pol κ was observed to favor extension from the correct 
base pairing dG-N
2
-IQ:C at both G1 and G3 (Figure 3-09). Therefore pol κ was observed to 
participate primarily in error-free TLS in vitro. Although pol κ was observed to favor extension 
from dG-N
2
-IQ:C, pol κ was observed to extend from dG-N2-IQ (1.27) mismatch base pairs. This 
indicates pol κ may contributes to TLS yielding G→A transversions and G→T transitions 
observed in HEK293T cells. In the in vitro assays, there was at least some extension from dG-
N
2
-IQ:N, where N is A or T, by TLS pols ζ, η, and κ  as well as, extension from dG-N2-IQ:A by 
pol ι. Therefore, the in vitro assay indicates that each pol investigated has at least some 
participation in error-prone TLS which is consistent with cellular study. 
The results of the previous and current in vitro TLS assays in combination with the 
cellular assay in HEK293T cells suggest the primary mutation observed G→T transversions arise 
from the misinsertion of A opposite dG-N
2
-IQ (1.27) by pol η followed by the cooperative 
extension from the lesion site by pols ζ and η (Figure 3-10). The compiled data also indicates the 
minor mutation, G→A transitions, observed results from misinsertion of T opposite dG-N2-IQ 
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(1.27) by pol ι followed by the cooperative extension by pols ζ and η (Figure 3-10). In general, in 
vitro assays suggest extension from insertion of T by pol ι is less efficient than the insertion of A, 
and the extension from A also appeared more prevalent. This is likely the reason that G→T 
transversions are predominant over G→A transitions. 
Pol ζ
Pol ι
TC
Pol ζ
GA
Pol η
A
GT
Pol η Pol ηPol κ
Pol κ
Figure 3-10: Summary primary TLS results for dG-N
2
-IQ. 
 
Comparison of the TLS of C8- and N
2
-IQ Guanine lesions 
The percentage of TLS in HEK293T cells is greater for the C8 adduct than for the N
2 
adduct of IQ at G1, G2, and G3 of the NarI site. This indicates that the dG-C8-IQ (1.26) is more 
readily bypassed than dG-N
2
-IQ (1.27).
13
 For the C8 adduct, the structural position of the adduct, 
minor groove (G1 and G2) or intercalated (G3), was dependent on sequence, but the adduct was in 
the syn conformation at all positions.
23
 However, dG-N
2
-IQ (1.27) is intercalated at both G1 and 
G3 and in the anti-conformation and only minor local differences in duplex structure are 
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reported, which indicates that the structural position of dG-N
2
-IQ (1.27) in the duplex is not 
greatly affected by sequence.
7, 8
 The position of the C8- or N
2
-IQ in the NarI sequence had only 
small impact on the level of TLS performed and the MF observed. This is most likely related to 
structure of the adduct within the duplex. For the dG-C8-IQ (1.26) lesion, the percentage of TLS 
performed and MF were greatest at G3 and lowest at G1, G3 > G2 > G1. The trend in percentage of 
TLS performed and MF was exactly the opposite for the N
2
-IQ lesion, G1 > G2 > G3. This is most 
likely related to the structure of the adduct and the local sequence within the duplex. For 
example, in vitro replication of N
2
-IQ at the iterated G3 induced –2 deletions, while C8-IQ did 
not. The two base deletion in vitro assays indicates the template may slip when N
2
-IQ is at G3, 
meaning that the lesion and 5ʹ neighbor base are bulged outside of the duplex. A slipped template 
is likely more difficult for TLS polymerases to process and may account for the level of TLS 
performed being the lowest in processing dG3-N
2
-IQ. The efficiency of the TLS polymerases 
required to process either the C8- or the N
2
-IQ lesions were affected by the position at which dG 
was modified within the NarI sequence. Pol η was essential for error free TLS of the C8-IQ 
lesion, while pol κ was essential for error-free TLS of the N2-IQ lesion both in vitro and in 
HEK293T cells. The results of the in vitro  and cellular studies implicated each of the 
polymerases investigated in the error-prone TLS of IQ adducts to some extent. The error-prone 
TLS of IQ adducts yielded primarily G→T transversions and to a lesser extent G→A transitions 
in HEK293T cells. For both dG-C8 and N
2
-IQ adducts, replication by pol ι was minor in both in 
vitro and in cellular studies. Pol ι was observed to contribute to error-prone TLS primarily 
through the insertion of dTTP opposite of the lesion and through one base extension from dG1-
IQ:A and dG3-N
2
-IQ. Interestingly, Rev1 was observed to insert dCTP opposite of dG-N
2
-IQ 
(1.27) but not dG-C8-IQ (1.26). Rev1 is suggested to favor insertion opposite N
2
-guanine 
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adducts.
15
 For the C8-IQ adduct, pol κ and ζ were both essential in error-prone TLS.13 The 
results suggest that the polymerases cooperatively bypass the C8 lesion. The in vitro results 
indicate that the insertion of the first primer base 3ʹ to the lesion was rate limiting for pol κ. It is 
therefore proposed that pol ζ and pol κ cooperate in lesion bypass, wherein pol ζ inserts the 
initial base(s) 3ʹ to the lesion followed by extension by pol κ to the point that normal replication 
can resume. For the N
2
-IQ adduct, single knockdown of either pol η or ζ produced a similar 
reduction in MF, however, the double knockdown of  both η and ζ produced a significant 
Pol ζ
Pol κ
Pol η
Pol ι
T
Pol η
C
Pol ζ
GA
Pol κ
Pol η
A
GT
 Figure 3-11: Summary primary TLS results for dG-C8-IQ. 
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reduction in MF. This indicates that both enzymes are responsible for the error-prone TLS of dG-
N
2
-IQ (1.27) and may cooperate in bypass of the lesion. Both pol η and ζ were observed to favor 
error-prone processing of dG-N
2
-IQ (1.27) in vitro. In conclusion, our results indicate that the 
error-free bypass of IQ adducts is performed by pol η for dG-C8-IQ (1.26) and by pol κ for N2-
IQ (Figures 3-10 and 3-11). Our results also suggest pol κ and ζ are primarily responsible for 
error-prone TLS of dG-C8-IQ (1.26), while pol η and ζ are primarily responsible for error-prone 
TLS of dG-N
2
-IQ (1.27) (Figure 3-10 and 3-11). 
 
Experimental Procedures 
Materials. yPol ζ, hPol κ, and hpol ι were purchased from Enzymax (Lexington, KY). 
hRev1 was either a gift from the laboratory of F. P. Geungerich (Vanderbilt University, 
Nashville, Tn) or purchased from Enzymax (Lexington, KY). The catalytic core of hPol η was a 
gift from the laboratory of Martin Egli at Vanderbilt University (Nashville, TN). The dNTP 
solutions (100 mM) were purchased from New England Biolabs (Ipswich, MA) or GE 
Healthcare (formerly Amersham Biosciences, Piscataway, NJ). [γ–32P]ATP was purchased from 
Perkin Elmer (Waltham, MA). dG-N
2
-IQ (1.27) modified oligonucleotides were prepared as 
previously reported.
6
 Unmodified oligonucleotides were purchased from Midland Certified 
Reagents (Midland, TX). 
Labeling and Annealing of Oligonucleotides. The primer was 5´ end-labeled with [γ-
32
P]ATP using T4 polynucleotide kinase (New England Biolabs, Ipswich, MA) according to the 
manufacturer’s instructions and purified on a Biospin column (BioRad, Hercules, CA). Each 
template and the respective 
32
P-labeled primer (1:1 molar ratio) were annealed in Tris-HCl buffer 
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(50 mM, pH 7.5) by heating at 90 °C for 5 min and then slowly cooling to room temperature (r. 
t.) in accordance with previously published procedure.
6
   
Single-Nucleotide Incorporation Assays. 
32
P-labeled primers were annealed to either 
the unmodified or the dG-N
2
-IQ (1.27) modified template, and extension reactions were then 
carried out in the presence of single dNTPs. All reactions were initiated by the addition of the 
dNTP solution (100 µM) to preincubated enzyme/DNA mixtures giving a final reaction volume 
of 20 µL. The final concentrations of the components for the incorporation assays were in Tris-
HCl (50 mM, pH 7.5), DNA duplex (10 nM), ypol ζ (2.5, 5, or 10 nM) or Rev1 (2.5, 5, or 10 
nM), dithiothreitol (DTT, 5 mM), bovine serum albumin (BSA, 50 µg/mL-1), NaCl (50 mM), 
and MgCl2 (5 mM). The ypol ζ reactions were run at 37 °C for 2 hr. Reactions were quenched 
with equal volume of EDTA (20 µL, 20 mM) in 95% formamide (v/v) containing xylene cyanol 
and bromophenol blue dyes. Aliquots (20 µL) were separated by electrophoresis on a denaturing 
gel containing urea (8.0 M) and 16 % acrylamide (w/v) (from a 19:1 acrylamide/bisacrylamide 
solution, AccuGel, National Diagnostics, Atlanta, GA) with Tris borate buffer (80 mM, pH 7.8) 
containing EDTA (1 mM). The gel was exposed to a PhosphorImager screen (Imaging Screen K, 
Bio-Rad) overnight. The bands were visualized with a PhosphorImaging system (Bio-Rad, 
Molecular Imager FX) using the manufacturer’s Quantity One software, version 4.3.0. 
Full-Length Extension Assay with All Four dNTPs. The unmodified or dG-N
2
-IQ 
(1.27) modified template was annealed to the 
32
P-labeled 0-primers (with a 3’-C, A, or T) and 
extended in the presence of all four dNTPs (100 µM each) at 37 °C. Reaction times were 2hr for 
ypol ζ, 5 hr for pol κ, and 30 min for pol ι and the catalytic core of hpol η for 30min. Each 
reaction was initiated by adding the mixture of the dNTP solution to a preincubated 
enzyme/DNA mixtures in Tris-HCl (50 mM, pH 7.5) buffer containing DNA duplex (10 nM), 
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ypol ζ (2.5, 5.0, and 10.0 nM), hPol κ  (0.2, 0.4, 1.0, 2, and 3.3 nM), hpol ι (0.2, 0.4, 1.0, 2, and 
3.3 nM), or hpol η (0.2, 0.4, 1.0, 2, and 3.3 nM), DTT (5 mM), BSA (50 µg/mL-1), NaCl (50 
mM), and MgCl2 (5 mM), giving a final reaction volume of 20 µL. Reactions were quenched by 
the addition of equal volume of EDTA (20 mM) in 95% formamide (v/v) containing xylene 
cyanol and bromophenol blue dyes. Aliquots (20 µL) were separated by electrophoresis on a 
denaturing gel containing urea (8.0 M) and 16 % acrylamide (w/v) (from a 19:1 
acrylamide/bisacrylamide solution, AccuGel, National Diagnostics, Atlanta, GA) with Tris 
borate buffer (80 mM, pH 7.8), containing EDTA (1 mM). Gels were exposed to a 
PhosphorImager screen (Imaging Screen K, Bio-Rad) overnight. The bands were visualized with 
a PhosphorImaging system (Bio-Rad, Molecular Imager FX) using the manufacturer’s Quantity 
One software, version 4.3.0. 
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CHAPTER IV 
 
SUMMARY: REPLICATION OF C8- AND N
2
-DEOXYGUANOSINE OF 
2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE (IQ) ADDUCT 
 
Introduction 
 2-Amino-3-methylimidazo[4,5-f]quinoline (IQ) is carcinogenic in laboratory animals 
including non-human primates, and has been classified as "reasonably anticipated to be a human 
carcinogen" by the National Toxicology Program.
1
 IQ is formed when meats are cooked at 
normal temperatures through the Maillard reaction.  Exposure to IQ occurs through the ingestion 
of meats prepared at normal cook temperatures.
2,3
 Ingested IQ is activated in the liver toward 
adduction at guanine sites of DNA.
4
 
 
The Role of TLS Polymerases in Replication of dG-IQ Adducts 
Bulky DNA adducts such as dG-C8-IQ (1.26) and dG-N
2
-IQ (1.27) are known to block 
DNA replication. The C8 and N
2
-IQ adducts of dG are a strong block to in vitro TLS by pol δ.5 
In addition, the carbocyclic anaolog of dG-C8-IQ (1.26) inhibited replication by E. coli DNA 
polymerase I, exo-free Klenow fragment, exo-free DNA polymerase II, and Dpo4.
6
 Previously, 
human pol η was the only pol identified to efficiently insert opposite both dG-C8-IQ (1.26) and 
dG-N
2
-IQ (1.27) and then extend the primers beyond dG-C8-IQ and dG-N
2
-IQ (1.26) adduct 
sites in vitro. Pol κ and ι were shown to insert opposite the lesion dG-C8-IQ and -N2-IQ lesions; 
however, further extension of primers was only observed from dG-N
2
-IQ adduct site. 
6
   
In recent studies, TLS pols ζ, Rev1, κ, ι, and η are implicated in the TLS of the dG-N2-IQ 
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and dG-C8-IQ lesions through siRNA knockdown of the TLS pols in HEK293T cells.
7
,
8
 
However, TLS was not wholly dependent upon any one polymerase, as was the case for the C8-
dG adduct of 3-nitrobenzanthrone (dG-C8-ABA).
9
 The TLS of the IQ lesions was examined at 
each guanine in the NarI recognition sequence (5ʹ-G1G2CG3CC-3ʹ), a hotspot for frameshift 
mutations.
8
 However, the mutations induced in HEK293T cells for both dG-C8-IQ and -N
2
-IQ 
were point mutations; no frameshift mutations were observed.
8
 The majority of mutations 
observed were GT transversions, although some GA transitions were also seen. In these 
studies, the percentage of TLS in wildtype cells (absence of knockdown) transfected with dG-N
2
-
IQ was approximately half the percentage of TLS observed in HEK293T cells containing the dG-
C8-IQ adduct (Figure 2-01 and 3-01). The low percentage of TLS observed for dG-N
2
-IQ 
implies the lesion participates in a greater number of blocked replication events than dG-C8-IQ 
lesion. These blocked replication events could lead to strand breaks. The roles of the TLS pols ζ, 
Rev1, κ, ι, and η were revealed by evaluating the mutation frequencies induced by IQ lesions 
when TLS pols were knocked down in HEK 293T cells (Figure 2-02 and 3-02).
8
 An increase in 
mutation frequency was observed for dG-C8-IQ (1.26) and dG-N
2
-IQ (1.27) when pol η and pol 
κ were respectively knocked down (Figure 2-02 and 3-02). Therefore, the pol η plays a role in 
non-mutagenic bypass of dG-C8-IQ (1.26) and pol κ plays a role in non-mutagenic bypass of 
dG-N
2
-IQ (1.27). The knockdown of the other TLS pols ζ, Rev1, κ, and ι for dG-C8-IQ (1.26) 
and pols ζ, Rev1, ι, and η for dG-N2-IQ (1.27) resulted in a decrease in MF, indicating a role in 
mutagenic bypass (Figure 2-02 and 3-02). For the individual adduct dG-C8-IQ (1.26) or dG-N
2
-
IQ (1.27), the roles of the TLS polymerases in non-mutagenic or mutagenic bypass of the 
respective adduct were independent of the position of the adducted G in the NarI site, even 
though the conformation of dG-C8-IQ changes depending on the position (Figure 2-02 and 3-
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02).
10
 The conformation of dG-C8-IQ is syn about the glycosidic bond at all positions, and 
intercalated at G3 and minor groove bound at G1 and G2.
10
 For comparison, the conformation of 
dG-N
2
-IQ is anti about glycosidic bond and intercalated at G1
 
and G3.
11,12
 The difference between 
the enzymes primarily responsible for non-mutagenic bypass of dG-C8-IQ (1.26) and dG-N
2
-IQ 
(1.27) is significant. The literature available suggests the difference is related to the size of the 
adduct and whether the C8 or N
2
 atom of dG is modified.
13,14
 The suggested roles are that pol η 
has difficulty bypassing bulky N
2
-guanine adducts, while pol κ is highly proficient at bypassing 
bulky N
2
-guanine adducts. The mutation frequency observed for dG-C8-IQ (1.26) and dG-N
2
-IQ 
(1.27) lesion were greatest at G3 and G1 of the NarI site, respectively (Figure 2-02 and 3-03). A 
study showing pol κ preferentially participates in bypass of bulky N2-guanine adducts suggest the 
TLS polymerase participation in bypass maybe significantly impacted position of dG 
modification (C8 or N
2
).
13
 Our results where pol η has a role in non-mutagenic bypass of dG-C8-
IQ (1.26) and pol κ has a role in non-mutagenic bypass of dG-N2-IQ (1.27) support these 
findings.
8
 The small discrepancies in mutation frequency observed for each adduct may be 
related to adduct conformation and local sequence.
10,11,12 
In cellular studies, dG-C8-IQ (1.26) and dG-N
2
-IQ (1.27) induced primarily G→T 
transversions and a minor amount of G→A transitions in HEK293T cells; importantly, no 
frameshift mutations were observed.
8
 As mentioned, siRNA knockdown studies suggest that pol 
η and κ, respectively are essential for the error-free bypass of the dG-C8-IQ (1.26) and dG-N2-IQ 
(1.27) lesions in HEK293T cells. Double knockdown reduced MF to less than 5%for dG-C8-IQ 
(1.26) with pols κ/ζ and for dG-N2-IQ (1.27) with pols η/ζ. These results indicate the enzymes 
pols κ/ζ and pols η/ζ are significant in mutagenic bypass of the respective lesions. Thus, pols ζ/κ 
and pols η/ζ are implicated in the generation of the observed base substitution mutations induced 
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by dG-C8-IQ (1.26) and dG-N
2
-IQ (1.27) in HEK293T cells.
8
 Pol η and ι were previously 
associated with these observed mutations through the observation that pol η will insert dATP and 
pol ι will insert dTTP opposite of the dG-C8-IQ (1.26) and dG-N2-IQ (1.27) in vitro. However, 
when misinsertion occurred, pol η and ι did not extend from the misinserted bases.5 Therefore, 
the polymerases responsible for extending the dG-C8-IQ (1.26) and dG-N
2
-IQ (1.27) mispaired 
primer termini were unknown. The role of TLS polymerases ζ, Rev1, κ, ι, and η in contributing 
to the G→T transversions and G→A transitions were further examined through in vitro 
extension from the primer terminus dG-C8-IQ:N and dG-N
2
-IQ:N, where N is C, A, or T at both 
the G1 and the iterated G3 position of the NarI site.
8
 Pol ζ and Rev1 were also evaluated for the 
ability to insert nucleotides opposite of the dG-IQ lesions. Pol ζ was incapable of insertion for 
both lesions. The lack of insertion by pol ζ is consistent with reports that pol ζ acts primarily as 
an extender.
15, 16
 Rev1 was  able to insert C opposite of dG-N
2
-IQ (1.26) in vitro, but not the dG-
C8-IQ (1.27) (Figure 2-04 and 3-04). Rev1 is suggested to favor insertion opposite N
2
-guanine 
adducts.
17
 The overall results of the in vitro and cellular studies implicated each of the 
polymerases investigated in the error-prone TLS of IQ adducts to some extent. For both adducts, 
dG-C8-IQ:N and dG-N
2
-IQ:N, where N is C, A, or T, replication by pol ι was minor both in vitro 
and in cellular studies. Pol ι was observed to contribute to error-prone TLS primarily through the 
insertion of dTTP opposite of the lesion and through one base extension from dG1-C8 and dG1-
N
2
-IQ:A and dG3-N
2
-IQ:A (Figure 2-07 and 3-07). For the C8-IQ adduct, the reduction in MF 
upon double knockdown of pol κ and ζ indicated both pols were essential in error-prone TLS in 
HEK293T cells (Figure 2-02).
8
 The results suggest that the polymerases cooperatively bypass the 
C8 lesion. The in vitro results indicate that the insertion of the first primer base 3ʹ to the lesion 
was rate limiting for pol κ (Figure 2-06).  
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It is therefore proposed that pol ζ and pol κ cooperate in lesion bypass, wherein pol ζ 
inserts the initial base(s) 3ʹ to the lesion followed by extension by pol κ to the point where 
replicative polymerases can resume (Figure 2-05 and 2-06).
8
 For the N
2
-IQ adduct, single 
knockdown of either pol η or ζ produced a similar reduction in MF; however, the double 
knockdown of both η and ζ produced a significant reduction in MF (Figure 3-02). This indicates 
that both enzymes are responsible for the error-prone TLS of dG-N
2
-IQ (1.27) and may 
cooperate in bypass of the lesion. Both pol η and ζ were observed to favor error-prone processing 
of dG-N
2
-IQ (1.27) in vitro (Figure 3-06 and Figure 3-08). In conclusion, our results indicate that 
the error-free bypass of IQ adducts is performed by pol η for dG-C8-IQ (1.26) and by pol κ for 
N
2
-IQ (Figures 3-10 and 3-11).
8
 Our results also suggest pol κ and ζ are primarily responsible for 
error-prone TLS of dG-C8-IQ (1.26), while pol η and ζ are primarily responsible for error-prone 
TLS of dG-N
2
-IQ (1.27) (Figure 3-10 and 3-11).
8
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